Transition metal catalyst compositions and methods for sequencing by synthesis
Transition metal catalysts with non-reducing phosphine ligands and boron-containing reducing agents effectively cleave 3' hydroxyl capping groups in nucleotides, addressing palladium interference and enhancing nucleic acid sequencing accuracy and read length.
Patent Information
- Application Number
- CN202380031858.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-22
- Filing Date
- 2023-12-20
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing nucleic acid sequencing methods face challenges in optimizing the performance of compositions used for sequencing by synthesis, particularly due to interference from palladium catalysts that adhere to DNA and affect binding with polymerase, leading to increased phasing and signal degradation.
The use of transition metal catalysts, such as palladium or nickel complexes with water-soluble non-reducing phosphine ligands and boron-containing reducing agents, to cleave the 3' hydroxyl capping groups of incorporated nucleotides, followed by a washing step to remove palladium scavengers, optimizing the sequencing process.
This approach enhances sequencing accuracy and read length by minimizing palladium interference, improving the integrity of DNA sequencing and reducing signal degradation.
Smart Images

Figure CN119095983A_ABST
Abstract
Description
background Technical Field
[0002] The present disclosure generally relates to polynucleotide sequencing methods, compositions, and kits for sequencing. The present disclosure also relates to methods for removing capping groups. Background Art
[0003] Progress in molecular research has always been driven, in part, by improvements in techniques used to characterize molecules or their biological reactions. In particular, the study of nucleic acids DNA and RNA has benefited from the development of techniques for sequence analysis and the study of hybridization events.
[0004] An example of the technology of improved nucleic acid research is to develop an assembly array of immobilized nucleic acids. These arrays are usually composed of a high-density matrix of polynucleotides fixed to a solid support material. See, for example, Fodor et al., Trends Biotech. 12: 19-26, 1994, which describes a method for assembling nucleic acids using a chemically sensitized glass surface, which is protected by a mask but exposed in a limited area to allow the connection of appropriately modified nucleotide phosphoramidites. Assembly arrays can also be manufactured by "spotting" known polynucleotides to predetermined positions on a solid support (e.g., Stimpson et al., Proc. Natl. Acad. Sci. 92: 6379-6383, 1995).
[0005] One method of determining the nucleotide sequence of nucleic acids bound to an array is known as "sequencing by synthesis" or "SBS". Ideally, this technique for determining the nucleotide sequence of DNA requires the controlled incorporation (i.e., one at a time) of the correct complementary nucleotide opposite to the nucleic acid being sequenced. This enables accurate sequencing by adding nucleotides in multiple cycles, since only one nucleotide residue is sequenced at a time, thereby preventing uncontrolled incorporation of nucleotide sequences. The incorporated nucleotides are read using an appropriate label attached to the incorporated nucleotides, after which the label portion is removed and the next round of sequencing is performed.
[0006] In order to ensure that only a single nucleotide is incorporated, a structural modification ("protecting group" or "capping group") is included in each labeled nucleotide, which is added to the growing chain to ensure that only one nucleotide is incorporated. After the nucleotide with the protecting group is added, the protecting group is removed under reaction conditions that do not interfere with the integrity of the DNA being sequenced. The sequencing cycle can then continue with the incorporation of the next protected labeled nucleotide. In order to be used for DNA sequencing, nucleotides (usually nucleotide triphosphates) generally require a 3'-hydroxyl capping group so that once a base is added to the nucleotide, the polymerase used to incorporate it into the polynucleotide chain is prevented from continuing to replicate.
[0007] Each step of the sequencing cycle uses a different composition. For example, an incorporation composition comprising a polymerase and one or more different types of nucleotides is used during the incorporation step. The scanning composition can include an antioxidant in particular, which protects the polynucleotide from light-induced damage during the detection step, for example, when the nucleotide includes a fluorophore label for detection. During the deblocking step, a deblocking composition is used, which includes a reagent for cleaving the blocking portion (e.g., 3' hydroxyl blocking group) from the incorporated nucleotide. Cleavage reagents, such as palladium (Pd) catalysts prepared from palladium complexes in the presence of water-soluble phosphine ligands, have been reported in deblocking compositions, for example, U.S. Publication Nos. 2020 / 0216891 and 2021 / 0403500, each of which is incorporated by reference in its entirety. Pd has the ability to adhere to DNA primarily in its inactive Pd (II) form, which may interfere with the binding between DNA and polymerase, thereby resulting in increased phasing. After the unblocking step, a post-cleavage washing composition comprising a Pd scavenger compound can be used. For example, PCT Publication No. WO 2020 / 126593 discloses that Pd scavengers (such as 3,3'-dithiodipropionic acid (DDPA) and lipoic acid (LA)) can be included in the scanning composition and / or the post-cleavage washing composition. The purpose of using these scavengers in the post-cleavage washing solution is to remove Pd(0) and convert Pd(0) into an inactive Pd(II) form, thereby improving the pre-phase value and sequencing indicators, reducing signal degradation, and extending the sequencing read length. However, there is a continuous demand for developing compositions for each step of sequencing to optimize performance. Summary of the invention
[0008] One aspect of the present disclosure relates to a method for determining the sequence of a plurality of target polynucleotides, the method comprising:
[0009] (a) contacting a solid support with a sequencing primer under hybridization conditions, wherein the solid support comprises a plurality of target polynucleotides immobilized thereon; and the sequencing primer is complementary to at least a portion of the target polynucleotide;
[0010] (b) contacting the solid support with a first aqueous solution under conditions suitable for DNA polymerase-mediated primer extension, the first aqueous solution comprising a DNA polymerase and one or more types of nucleotides among four different types of nucleotides, wherein each of the nucleotides comprises a 3' blocking group comprising an unsubstituted or substituted allyl group;
[0011] (c) incorporating one type of nucleotide into the sequencing primer to produce an extended copy polynucleotide;
[0012] (d) performing one or more fluorescence measurements on the extended copy polynucleotide;
[0013] (e) removing the 3' blocking group of the incorporated nucleotide in a second aqueous solution comprising a transition metal catalyst generated from a palladium or nickel complex with a water-soluble non-reducing phosphine or N,N-bidentate non-phosphine ligand and one or more reducing agents, and wherein the one or more reducing agents include a boron-containing reducing agent; and
[0014] (f) After removing the 3' blocking group of the incorporated nucleotide, washing the solid support with a third aqueous solution.
[0015] Another aspect of the present disclosure relates to a kit for use with a sequencing device, the kit comprising: an aqueous lysis mixture, the aqueous lysis mixture comprising a transition metal catalyst and one or more reducing agents, wherein the transition metal catalyst is produced by a palladium or nickel complex having a water-soluble non-reducing phosphine or an N,N-bidentate non-phosphine ligand, and wherein the one or more reducing agents include a boron-containing reducing agent.
[0016] Additional aspects of the present disclosure relate to a cartridge for use with a sequencing apparatus, the cartridge comprising a plurality of chambers, wherein a chamber of the plurality of chambers is used with a kit as described herein comprising an aqueous lysis mixture. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 It is a line graph of the percentage of cleavage of the 3' end group of the Pd(II) complexes mixed with a reduced phosphine ligand (THPP), a non-reducing phosphine ligand (TCEP) without a reducing agent, and a non-reducing phosphine ligand (TCEP) with a reducing agent (NH3BH3) as a function of time.
[0018] Figure 2 is a line graph of the percent cleavage of the 3' capping group as a function of time when the Pd(II) complex is mixed with the non-reducing phosphine ligand TCEP in the presence of a reducing agent at pH 7, compared to the standard universal cleavage mixture (UCM) at two different pHs (pH 7 and 9.5).
[0019] Figure 3 is a line graph of the percentage of cleavage of the 3' capping group as a function of time when the Pd(II) complex is mixed with 50% concentration of TCEP when compared to a standard UCM with either 100% or 50% palladium catalyst concentration.
[0020] Figure 4 It is iSeq in Illumina TMLine graph of percent phasing and percent prephasing as a function of sequencing cycles on the platform comparing the performance of a standard UCM and a Pd cleavage cocktail according to embodiments of the present disclosure.
[0021] Figure 5A The formation of Pd(0) using a standard universal cleavage mixture is demonstrated compared to palladium catalysts generated from N,N-bidentate non-phosphine ligands.
[0022] Figure 5B The percent cleavage yield of substrates containing an AOM group using a standard universal cleavage mixture compared to palladium catalysts generated from N,N-bidentate non-phosphine ligands is shown. DETAILED DESCRIPTION
[0023] Some aspects of the present disclosure relate to methods for nucleic acid sequencing, wherein transition metal catalyst activation includes separate coordination and reduction steps. Specifically, the sequencing methods described herein relate to the use of a transition metal catalyst, such as a palladium (Pd) catalyst or a nickel (Ni) catalyst with a non-reducing ligand, such as a water-soluble phosphine and a reducing agent to cleave the 3' hydroxyl end-capping group of the incorporated nucleotide before the next incorporation cycle. In some embodiments, the water-soluble phosphine includes a tri[substituted alkyl] phosphine. In some embodiments, the palladium (Pd) complex is a Pd(0) complex. In some embodiments, the nickel (Ni) complex is a Ni(0) complex. In some embodiments, the reducing agent comprises boron. Some aspects of the present disclosure generally relate to methods for removing end-capping groups.
[0024] definition
[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art. The use of the term "including" and other forms such as "include", "includes", and "included" is not restrictive. The use of the term "having" and other forms such as "have", "has", and "had" is not restrictive. As used in this specification, whether in a transitional phrase or in the body of the claim, the terms "including" and "comprising" will be interpreted as having an open meaning. That is, the above terms should be interpreted synonymously with the phrase "at least having" or "at least including". For example, when used in the context of a process, the term "comprising" means that the process includes at least the listed steps, but may also include additional steps. When used in the context of a compound, composition, or device, the term "comprising" means that the compound, composition, or device includes at least the listed features or components, but may also include additional features or components.
[0026] Where a range of values is provided, it is understood that the upper and lower limit of that range and every intervening value between the upper and lower limits is encompassed within the embodiments.
[0027] As used herein, common organic abbreviations are defined as follows:
[0028] ℃ Temperature in degrees Celsius
[0029] dATP deoxyadenosine triphosphate
[0030] dCTP deoxycytidine triphosphate
[0031] dGTP deoxyguanosine triphosphate
[0032] dTTP deoxythymidine triphosphate
[0033] ddNTP dideoxynucleotide triphosphate
[0034] ffN Fully functionalized nucleotides
[0035] ffA Fully functionalized "A" nucleotide
[0036] ffC Fully functionalized "C" nucleotides
[0037] ffT Fully functionalized "T" nucleotides
[0038] ffG Fully functionalized "G" nucleotides
[0039] IMX incorporation mixture (“Incorporation mix” or “Incorporation mixture”)
[0040] Nickel
[0041] Pd Palladium
[0042] RT Room temperature
[0043] SBS Sequencing by Synthesis
[0044] TCEP tris(2-carboxyethyl)phosphine
[0045] THPP tri(hydroxypropyl)phosphine
[0046] As used herein, the term "array" refers to a group of different probe molecules connected to one or more substrates so that these different probe molecules can be distinguished from each other according to relative position. The array may include different probe molecules at different addressable positions on the substrate. Alternatively or additionally, the array may include a separate substrate with different probe molecules, wherein different probe molecules can be identified according to the position of the substrate on the surface to which the substrate is connected or according to the position of the substrate in the liquid. The exemplary array in which the separate substrate is located on the surface includes but is not limited to those comprising beads in the hole, such as, for example, U.S. Patent No. 6,355,431B1, US2002 / 0102578 and PCT disclose described in No. WO 00 / 63437. For example, in U.S. Patent No. 6,524,793, it is described that the exemplary form of beads in the liquid array can be used for example using a microfluidic device, such as a fluorescence activated cell sorter (FACS) is distinguished in the present invention. Additional examples of arrays that can be used in the present invention include, but are not limited to, U.S. Patent Nos. 5,429,807; 5,436,327; 5,561,071; 5,583,211; 5,658,734; 5,837,858; 5,874,219; 5,919,523; 6,136,269; No. 6,287,768; No. 6,287,776; No. 6,288,220; No. 6,297,006; No. 6,291,193; No. 6,346,413; No. 6,416,949; No. 6,482,591; No. 6,514,751 and No. 6,610,482; and those described in WO93 / 17126; WO 95 / 11995; WO 95 / 35505; EP 742287; and EP 799 897.
[0047] As used herein, the term "covalently attached" or "covalently bonded" refers to the formation of a chemical bond characterized by the sharing of electron pairs between atoms. For example, a covalently attached polymer coating refers to a polymer coating that forms a chemical bond with a functionalized surface of a substrate, as opposed to adhering to the surface via other means (e.g., adhesion or electrostatic interactions). It should be understood that a polymer covalently attached to a surface may also be bonded via means other than covalent attachment.
[0048] As used herein, "activating" or "activating" a transition metal catalyst (e.g., a palladium catalyst or a nickel catalyst) includes, but is not limited to, (1) exposing an inactive form of a transition metal (e.g., Pd(II) or Ni(II)) to a reducing ligand to convert the transition metal to an active form (e.g., Pd(0) or Ni(0)), or (2) exposing an inactive form of a transition metal (e.g., Pd(II) or Ni(II)) to a non-reducing ligand and a reducing agent to convert the transition metal to an active form (e.g., Pd(0) or Ni(0)).
[0049] As used herein, "inactivating" or "inactivating" a palladium catalyst includes, but is not limited to, the following mechanisms using a palladium scavenger: (1) the palladium scavenger can act as a competitive substrate that consumes any remaining active Pd(0) attached to the nucleic acid; (2) the palladium scavenger can act as an oxidant that converts the active Pd(0) to the inactive Pd(II) form; and (3) the palladium scavenger can act as a competitive ligand that removes Pd (e.g., Pd(0) or Pd(II)) attached to the nucleic acid.
[0050] As used herein, any "R" group refers to a substituent that may be attached to the designated atom. The R group may be substituted or unsubstituted.
[0051] It should be understood that, depending on the context, certain group naming conventions may include a monoradical or a diradical. For example, when a substituent requires two points of attachment to the rest of the molecule, it should be understood that the substituent is a diradical. For example, a substituent identified as an alkyl group requiring two points of attachment includes a diradical, such as -CH2-, -CH2CH2-, -CH2CH(CH3)CH2-, etc. Other group naming conventions clearly indicate that the group is a diradical, such as "alkylene" or "alkenylene".
[0052] As used herein, the term "halogen" or "halo" means any of the radioactive stable atoms of column 7 of the periodic table, for example, fluorine, chlorine, bromine or iodine, with fluorine and chlorine being preferred.
[0053] As used herein, "C" wherein "a" and "b" are integers a -C b ”, “C a -C b " or "C a-b" refers to the number of carbon atoms in an alkyl, alkenyl, or alkynyl group, or the number of ring atoms in a cycloalkyl or aryl group. That is, the rings of alkyl, alkenyl, alkynyl, cycloalkyl, and aryl groups can contain from "a" to "b" (inclusive) carbon atoms. For example, a "C1 to C4 alkyl" group refers to all alkyl groups having from 1 to 4 carbons, i.e., CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2 CH2-, CH3CH2CH(CH3)- and (CH3)3C-; C3 to C4 cycloalkyl groups refer to all cycloalkyl groups having 3 to 4 carbon atoms, i.e., cyclopropyl and cyclobutyl. Similarly, a "4 to 6 membered heterocyclyl" group refers to all heterocyclyl groups having 4 to 6 total ring atoms, such as azetidine, oxetane, oxazoline, pyrrolidine, piperidine, piperazine, morpholine, etc. If there is no alkyl, alkenyl, alkynyl, cycloalkyl or aryl group, the alkyl group may be used. If "a" and "b" are specified, the broadest range described in these definitions will be assumed. As used herein, the term "C1-C6" includes C1, C2, C3, C4, C5, and C6, as well as ranges defined by either of these two numbers. For example, C1-C6 alkyl includes C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl, C2-C6 alkyl, C1-C3 alkyl, etc. Similarly, C2-C6 alkenyl includes C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl, and C6 alkenyl. C3-C8 cycloalkyl groups include hydrocarbon rings containing 3, 4, 5, 6, 7 and 8 carbon atoms or ranges defined by any two numbers, such as C3-C7 cycloalkyl groups or C5-C6 cycloalkyl groups.
[0054] As used herein, "alkyl" refers to a straight or branched hydrocarbon chain that is fully saturated (i.e., does not contain double bonds and triple bonds). The alkyl group may have 1 to 20 carbon atoms (whenever it appears in this article, a numerical range such as "1 to 20" refers to each integer in the given range; for example, "1 to 20 carbon atoms" means that the alkyl group may be composed of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, but this definition also covers the term "alkyl" in which no numerical range is specified). The alkyl group may also be a medium-sized alkyl group with 1 to 9 carbon atoms. The alkyl group may also be a low-alkyl group with 1 to 6 carbon atoms. The alkyl group may be named "C1-C4 alkyl" or a similar name. By way of example only, "C 1-"C6 alkyl" means that there are one to six carbon atoms in the alkyl chain, that is, the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. Typical alkyl groups include, but are by no means limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.
[0055] As used herein, "alkoxy" refers to a radical of the formula -OR (wherein R is an alkyl radical as defined above), such as "C 1- "C9 alkoxy" includes, but is not limited to, methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, sec-butoxy and tert-butoxy, etc.
[0056] As used herein, "alkenyl" refers to a straight or branched hydrocarbon chain containing one or more double bonds. An alkenyl group may have from 2 to 20 carbon atoms, but this definition also encompasses the term "alkenyl" where no numerical range is specified. An alkenyl group may also be a medium-sized alkenyl group having from 2 to 9 carbon atoms. An alkenyl group may also be a lower alkenyl group having from 2 to 6 carbon atoms. An alkenyl group may be designated as "C 2- C6 alkenyl" or similar designations. By way of example only, "C 2- "C6 alkenyl" means that there are two to six carbon atoms in the alkenyl chain, that is, the alkenyl chain is selected from the group consisting of ethenyl, propen-1-yl, propen-2-yl, propen-3-yl, buten-1-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1-methyl-propen-1-yl, 2-methyl-propen-1-yl, 1-ethyl-ethen-1-yl, 2-methyl-propen-3-yl, buta-1,3-dienyl, buta-1,2-dienyl and buta-1,2-dien-4-yl. Typical alkenyl groups include, but are by no means limited to, ethenyl, propenyl, butenyl, pentenyl and hexenyl, etc.
[0057] The term "aromatic" refers to a ring or ring system having a conjugated π electron system, and includes both carbocyclic aromatic groups (e.g., phenyl) and heterocyclic aromatic groups (e.g., pyridine). The term includes monocyclic groups or fused-ring polycyclic (i.e., rings that share adjacent pairs of atoms) groups, provided that the entire ring system is aromatic.
[0058] As used herein, "aryl" refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent carbon atoms) that contains only carbon in the ring backbone. When aryl is a ring system, each ring in the ring system is aromatic. Aryl groups can have 6 to 18 carbon atoms, but this definition also covers the term "aryl" that appears without a specified numerical range. In some embodiments, aryl groups have 6 to 10 carbon atoms. Aryl groups can be designated as "C6-C 10 Aryl", "C6 or C 10Examples of aryl groups include, but are not limited to, phenyl, naphthyl, azulenyl, and anthracenyl.
[0059] "Aralkyl" or "arylalkyl" is an aryl group attached as a substituent through an alkylene group, such as "C 7-14 "Aralkyl" and the like, including but not limited to benzyl, 2-phenylethyl, 3-phenylpropyl and naphthylalkyl. In some cases, the alkylene group is a lower alkylene group (i.e., C 1- C6 alkylene group).
[0060] As used herein, "aryloxy" refers to RO-, where R is aryl as defined above, such as but not limited to phenyl.
[0061] As used herein, "heteroaryl" refers to an aromatic ring or ring system (i.e., two or more condensed rings sharing two adjacent atoms) containing one or more heteroatoms (i.e., elements other than carbon, including but not limited to nitrogen, oxygen and sulfur) in the ring skeleton. When heteroaryl is a ring system, each ring in the ring system is aromatic. The heteroaryl group can have 5 to 18 ring members (i.e., the number of atoms (including carbon atoms and heteroatoms) constituting the ring skeleton), but the present definition also encompasses the term "heteroaryl" in which no numerical range is specified. In some embodiments, the heteroaryl group has 5 to 10 ring members or 5 to 7 ring members. The heteroaryl group can be named "5 to 7 yuan heteroaryl", "5 to 10 yuan heteroaryl" or similar names. Examples of heteroaryl rings include, but are not limited to, furanyl, thienyl, phthalazinyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolyl, and benzothiophenyl.
[0062] "Heteroaralkyl" or "heteroarylalkyl" is a heteroaryl group attached as a substituent via an alkylene group. Examples include, but are not limited to, 2-thienylmethyl, 3-thienylmethyl, furanylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl. In some cases, the alkylene group is a lower alkylene group (i.e., C 1- C6 alkylene group).
[0063] As used herein, "carbocyclyl" means a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system skeleton. When the carbocyclyl is a ring system, two or more rings can be joined together in a fused, bridged or spiro manner. The carbocyclyl can have any degree of saturation, provided that at least one ring in the ring system is not aromatic. Therefore, carbocyclyl includes cycloalkyl, cycloalkenyl and cycloalkynyl. The carbocyclyl group can have 3 to 20 carbon atoms, but this definition also covers the term "carbocyclyl" in which no numerical range is specified. The carbocyclyl group can also be a medium-sized carbocyclyl with 3 to 10 carbon atoms. The carbocyclyl group can also be a carbocyclyl with 3 to 6 carbon atoms. The carbocyclyl group can be named "C 3- C6 carbocyclyl" or similar designations. Examples of carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3-dihydro-indene, bicyclo[2.2.2]octanyl, adamantyl, and spiro[4.4]nonanyl.
[0064] As used herein, "cycloalkyl" means a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0065] As used herein, "heterocyclyl" refers to a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. The heterocyclyl group can be joined together in a fused, bridged or spiro manner. The heterocyclyl group can have any degree of saturation, provided that at least one ring in the ring system is not aromatic. The heteroatom can be present in a non-aromatic ring or an aromatic ring in the ring system. The heterocyclyl group can have 3 to 20 ring members (i.e., the number of atoms (including carbon atoms and heteroatoms) constituting the ring backbone), but this definition also covers the term "heterocyclyl" in which no numerical range is specified. The heterocyclyl group can also be a medium-sized heterocyclyl group with 3 to 10 ring members. The heterocyclyl group can also be a heterocyclyl group with 3 to 6 ring members. The heterocyclyl group can be named "3 to 6-membered heterocyclyl" or similar names. In preferred six-membered monocyclic heterocyclyls, the heteroatoms are selected from one to a maximum of three from O, N or S, and in preferred five-membered monocyclic heterocyclyls, the heteroatoms are selected from one or two heteroatoms selected from O, N or S. Examples of heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidinedionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1,3-dioxinyl, 1,4-dioxinyl, 1,4-dioxinyl, 1,3-oxathianyl, 1,4-oxathianyl, 1,4-oxathianyl, 2 H-1,2-oxazinyl, trioxanyl, hexahydro-1,3,5-triazinyl, 1,3-dioxolyl, 1,3-dioxolanyl, 1,3-dithienyl, 1,3-dithianyl, isoxazolinyl, isoxazolidinyl, oxazolinyl, oxazolidinyl, oxazolidinone, thiazolinyl, thiazolidinyl, 1,3-oxathiolanyl, indolinyl, isoindolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydrothiopyranyl, tetrahydro-1,4-thiazinyl, thiomorpholinyl, dihydrobenzofuranyl, benzimidazolidinyl and tetrahydroquinoline.
[0066] As used herein, "(aryl)alkyl" refers to an aryl group as defined above attached as a substituent via an alkylene group as described above. The alkylene and aryl groups of the aralkyl group may be substituted or unsubstituted. Examples include, but are not limited to, benzyl, 2-phenylalkyl, 3-phenylalkyl, and naphthylalkyl. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.
[0067] As used herein, "(heteroaryl)alkyl" refers to a heteroaryl group as defined above attached as a substituent via an alkylene group as defined above. The alkylene and heteroaryl groups of the heteroaralkyl group may be substituted or unsubstituted. Examples include, but are not limited to, 2-thienylalkyl, 3-thienylalkyl, furanylalkyl, thienylalkyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl, and their benzo-fused analogs. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.
[0068] As used herein, "(heterocyclyl)alkyl" refers to a heterocycle or heterocyclyl group as defined above connected as a substituent via an alkylene group as defined above. The alkylene group and heterocyclyl group of the (heterocyclyl)alkyl can be substituted or unsubstituted. Examples include, but are not limited to, (tetrahydro-2H-pyran-4-yl)methyl, (piperidin-4-yl)ethyl, (piperidin-4-yl)propyl, (tetrahydro-2H-thiopyran-4-yl)methyl and (1,3-thiazin-4-yl)methyl. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5 or 6 methylene units.
[0069] As used herein, "(carbocyclyl)alkyl" refers to a carbocyclyl group (as defined herein) attached as a substituent via an alkylene group. Examples include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylethyl, and cyclohexylpropyl. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.
[0070] As used herein, "alkoxyalkyl" or "(alkoxy)alkyl" refers to an alkoxy group attached through an alkylene group, such as C2-C8alkoxyalkyl or (C1-C6alkoxy)C1-C6alkyl, for example -(CH2) 1-3 -OCH3.
[0071] As used herein, "-O-alkoxyalkyl" or "-O-(alkoxy)alkyl" refers to an alkoxy group attached via an -O-(alkylene) group, such as -O-(C1-C6alkoxy)C1-C6alkyl, e.g., -O-(CH2) 1-3 -OCH3.
[0072] As used herein, "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen (e.g., monohaloalkyl, dihaloalkyl, and trihaloalkyl). Such groups include, but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1-chloro-2-fluoromethyl, 2-fluoroisobutyl. The haloalkyl group may be substituted or unsubstituted.
[0073] As used herein, "haloalkoxy" refers to an alkoxy group in which one or more hydrogen atoms are replaced by a halogen (e.g., monohaloalkoxy, dihaloalkoxy, and trihaloalkoxy). Such groups include, but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 1-chloro-2-fluoromethoxy, 2-fluoroisobutoxy. The haloalkoxy group may be substituted or unsubstituted.
[0074] An "amino" group refers to an -NH2 group. As used herein, the term "monosubstituted amino group" refers to an amino (-NH2) group in which one hydrogen atom is replaced by a substituent. As used herein, the term "disubstituted amino group" refers to an amino (-NH2) group in which each of the two hydrogen atoms is replaced by a substituent. As used herein, the term "optionally substituted amino" refers to an -NR A R B Group, where R A and R B and R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl or heterocyclyl(alkyl), as defined herein.
[0075] An "O-carboxyl" group is one in which R is selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 Aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocyclyl "-OC(=O)R" groups are as defined herein.
[0076] A "C-carboxyl" group is one in which R is selected from the group consisting of hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 The "-C(=O)OR" group of the group consisting of aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocyclyl, as defined herein. Non-limiting examples include carboxyl (ie, -C(=O)OH).
[0077] A "sulfonyl" group is a group in which R is selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 The "-SO2R" group of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclyl are as defined herein.
[0078] A "sulfinyl" group refers to a "-S(=O)OH" group.
[0079] A "sulfo" group refers to a "-S(=O)2OH" or a "-SO3H" group.
[0080] The "sulfonate" group refers to "-SO3 - ” group.
[0081] The "sulfate" group refers to "-SO4 - ” group.
[0082] An "S-sulfonamido" group is one in which R A and R B are each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-SO2NR" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A R B " group, as defined herein.
[0083] An "N-sulfonamido" group is one in which R A and R B are each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-N(R)" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A )SO2R B " group, as defined herein.
[0084] A "C-amido" group is one in which R A and R B are each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-C(=O)NR" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A R B " group, as defined herein.
[0085] An "N-amido" group is one in which RA and R B are each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-N(R)" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A )C(=O)R B " group, as defined herein.
[0086] An "O-carbamyl" group refers to a "-OC(=O)N(R A R B )" group, wherein R A and R B The O-carbamyl group may be substituted or unsubstituted.
[0087] An "N-carbamyl" group refers to an "ROC(=O)N(R A ) - " group, where R and R A The same definition as for N-sulfonylamino may be used. The N-carbamoyl group may be substituted or unsubstituted.
[0088] An "O-thiocarbamyl" group refers to an "-OC(=S)-N(R A R B )" group, wherein R A and R B The O-thiocarbamoyl group may be substituted or unsubstituted.
[0089] An "N-thiocarbamyl" group refers to an "ROC(=S)N(R A )-" group, where R and R A The same definition as for N-sulfonylamino group may be used. The N-thiocarbamoyl group may be substituted or unsubstituted.
[0090] The term "alkylamino" or "(alkyl)amino" refers to an amino group in which one or both hydrogen atoms are replaced by an alkyl group.
[0091] An "(alkoxy)alkyl" group refers to an alkoxy group attached through an alkylene group, such as "(C 1- C6 alkoxy)C 1- C6 alkyl" etc.
[0092] The term "hydroxy" as used herein refers to an -OH group.
[0093] The term "cyano" as used herein refers to a "-CN" group.
[0094] The term "azido" as used herein refers to a -N3 group.
[0095] When a group is described as "optionally substituted," it may be unsubstituted or substituted. Likewise, when a group is described as "substituted," the substituents may be selected from one or more of the indicated substituents. As used herein, a substituted group is derived from an unsubstituted parent group in which there has been an exchange of one or more hydrogen atoms with another atom or group.Unless otherwise specified, when a group is considered to be "substituted", it means that the group is substituted by one or more substituents independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 heteroalkyl, C3-C7 carbocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), C3-C7 carbocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 3-10 membered heterocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 3-10 membered heterocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), aryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), (aryl)C1-C6 alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), (5-10 membered heteroaryl)C1-C6 alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), halo, -CN, hydroxy, C1-C6 alkoxy, (C1-C6 alkoxy)C1-C6 alkyl, -O(C1-C6 alkoxy)C1-C6 alkyl; (C1-C6 haloalkoxy)C1-C6 alkyl; -O(C1-C6 haloalkoxy) C1-C6 alkyl; aryloxy, thiol (sulfhydryl), halo(C1-C6)alkyl (e.g., -CF3), halo(C1-C6)alkoxy (e.g., -OCF3), C1-C6 alkylthio, arylthio, amino, amino(C1-C6)alkyl, nitro, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-acylamino, N-acylamino, S-sulfonylamino, N-sulfonylamino, C-carboxyl, O-carboxyl, acyl, cyanate, isocyanate, thiocyanate, isothiocyanate, sulfinyl, sulfonyl, -SO3H, sulfonate, sulfate, sulfinyl, -OSO2C. 1-4 Alkyl, monophosphate, diphosphate, triphosphate and oxo (=0). Wherever a group is described as "optionally substituted", the group may be substituted with the above substituents.
[0096] As will be appreciated by those of ordinary skill in the art, the compounds described herein may exist in an ionized form, for example, -CO2 - 、-SO3 - or -O-SO3 - If the compound contains a positively or negatively charged substituent group, e.g., -SO3 - , it may also contain negatively or positively charged counterions so that the compound is neutral overall. In other aspects, the compound may exist in the form of a salt, wherein the counterion is provided by a conjugate acid or base.
[0097] As used herein, "nucleotides" include nitrogenous heterocyclic bases, sugars, and one or more phosphate groups. They are monomeric units of nucleic acid sequences. In RNA, the sugar is ribose, and in DNA it is deoxyribose, i.e., a sugar lacking the hydroxyl groups present in ribose. The nitrogenous heterocyclic bases may be purine or pyrimidine bases. Purine bases include adenine (A) and guanine (G) and their modified derivatives or analogs, such as 7-deazaadenine or 7-deazaguanine. Pyrimidine bases include cytosine (C), thymine (T) and uracil (U) and their modified derivatives or analogs. The C-1 atom of deoxyribose is bonded to the N-1 of pyrimidine or the N-9 of purine.
[0098] As used herein, "nucleoside" is structurally similar to a nucleotide, but lacks a phosphate moiety. An example of a nucleoside analog is a nucleoside analog in which a label is attached to a base and no phosphate group is attached to a sugar molecule. The term "nucleoside" is used herein in the conventional sense as understood by those skilled in the art. Examples include, but are not limited to, ribonucleosides comprising a ribose moiety and deoxyribonucleosides comprising a deoxyribose moiety. A modified pentose moiety is a pentose moiety in which an oxygen atom has been replaced by a carbon and / or a carbon has been replaced by a sulfur or oxygen atom. A "nucleoside" is a monomer that may have a substituted base and / or sugar moiety. In addition, nucleosides may be incorporated into larger DNA and / or RNA polymers and oligomers.
[0099] The term "purine base" is used herein with the common meaning understood by those skilled in the art, and includes its tautomers. Similarly, the term "pyrimidine base" is used herein with the common meaning understood by those skilled in the art, and includes its tautomers. The non-limiting list of optionally substituted purine bases includes purine, adenine, guanine, deazapurine, 7-deazaadenine, 7-deazaguanine, hypoxanthine, xanthine, alloxanthine, 7-alkylguanine (e.g., 7-methylguanine), theobromine, caffeine, uric acid, and isoguanine. The example of pyrimidine bases includes, but is not limited to, cytosine, thymine, uracil, 5,6-dihydrouracil, and 5-alkylcytosine (e.g., 5-methylcytosine).
[0100] As used herein, when an oligonucleotide or polynucleotide is described as "comprising" or "incorporating" a nucleoside or nucleotide as described herein, this means that a nucleoside or nucleotide as described herein forms a covalent bond with an oligonucleotide or polynucleotide. Similarly, when a nucleoside or nucleotide is described as a part of an oligonucleotide or polynucleotide, such as "incorporating" an oligonucleotide or polynucleotide, this means that a nucleoside or nucleotide as described herein forms a covalent bond with an oligonucleotide or polynucleotide. In some such embodiments, a covalent bond is formed between the 5' phosphate group of the nucleotide of the 3' hydroxyl of an oligonucleotide or polynucleotide and the 5' carbon atom of the phosphodiester bond described herein as a 3' carbon atom of an oligonucleotide or polynucleotide and a nucleotide.
[0101] As used herein, the term "cleavable linker" is not intended to imply that the entire linker needs to be removed. The cleavage site can be located at a position on the linker that ensures that a portion of the linker remains attached to the detectable label and / or nucleoside or nucleotide moiety after cleavage.
[0102] As used herein, "derivative" or "analog" means a synthetic nucleotide or nucleoside derivative with a modified base moiety and / or a modified sugar moiety. Such derivatives and analogs are discussed in, for example, Scheit, Nucleotide Analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90: 543-584, 1990. Nucleotide analogs can also include modified phosphodiester bonds, including phosphorothioate bonds, phosphorodithioate bonds, alkylphosphonate bonds, aniline phosphate bonds and phosphoramidate bonds. As used herein, "derivative", "analog" and "modified" can be used interchangeably, and are covered by the terms "nucleotide" and "nucleoside" defined herein.
[0103] As used herein, the term "phosphate" is used with the ordinary meaning understood by those skilled in the art and includes its protonated form (e.g., ). As used herein, the terms "monophosphate," "diphosphate," and "triphosphate" are used with their ordinary meaning as understood by those skilled in the art, and include protonated forms.
[0104] As used herein, the term "protecting group" refers to any atom or group of atoms added to a molecule in order to prevent existing groups in the molecule from undergoing undesired chemical reactions. Sometimes, "protecting group" and "capping group" can be used interchangeably.
[0105] As used herein, the term "phasing" refers to a phenomenon in SBS, which is caused by the incomplete removal of 3' terminators and fluorophores and the failure to complete the incorporation of a portion of the DNA chain in the cluster by polymerase under a given sequencing cycle. Prephasing is caused by the incorporation of nucleotides that do not have an effective 3' terminator, wherein the incorporation event is advanced by 1 cycle due to termination failure. Phasing and prephasing cause the measured signal intensity of a specific cycle to be composed of the signal from the current cycle and the noise from the previous and next cycles. As the number of cycles increases, the sequence score of each cluster affected by phasing and prephasing increases, hindering the identification of the correct base. Prephasing can be caused by the presence of traces of unprotected or uncapped 3'-OH nucleotides during sequencing by synthesis (SBS). Unprotected 3'-OH nucleotides can be produced during the manufacturing process or may be stored and during the reagent handling process. Therefore, the discovery of nucleotide analogs that reduce the incidence of prephasing is surprising, and provides greater advantages than existing nucleotide analogs in SBS applications. For example, the provided nucleotide analogs can lead to faster SBS cycle times, lower phasing and prephasing values, and longer sequencing read lengths.
[0106] Sequencing method using transition metal catalyst, non-reducing ligand and reducing agent
[0107] Some embodiments of the present disclosure relate to a method for determining the sequence of a plurality of target polynucleotides (e.g., single-stranded polynucleotides), the method comprising:
[0108] (a) contacting a solid support with a sequencing primer under hybridization conditions, wherein the solid support comprises a plurality of target polynucleotides immobilized thereon; and the sequencing primer is complementary to at least a portion of the target polynucleotide;
[0109] (b) contacting the solid support with a first aqueous solution under conditions suitable for DNA polymerase-mediated primer extension, the first aqueous solution comprising a DNA polymerase and one or more types of nucleotides among four different types of nucleotides, wherein each of the nucleotides comprises a 3' blocking group comprising an unsubstituted or substituted allyl group;
[0110] (c) incorporating one type of nucleotide into the sequencing primer to produce an extended copy polynucleotide;
[0111] (d) performing one or more fluorescence measurements on the extended copy polynucleotide;
[0112] (e) removing the 3' blocking group of the incorporated nucleotide in a second aqueous solution comprising a transition metal catalyst generated from a palladium or nickel complex with a water-soluble non-reducing phosphine or an N,N-bidentate non-phosphine ligand and one or more reducing agents; and
[0113] (f) After removing the 3' blocking group of the incorporated nucleotide, washing the solid support with a third aqueous solution.
[0114] In some embodiments of the methods described herein, the method further comprises repeating steps (b) to (f) until the sequence of at least a portion of the target polynucleotide is determined. In other embodiments, steps (b) to (f) are repeated at least 50 times, at least 100 times, at least 150 times, at least 200 times, at least 250 times, at least 300 times, at least 350 times, at least 400 times, at least 450 times, or at least 500 times.
[0115] In some embodiments of the methods described herein, the transition metal catalyst is a Pd(0) catalyst, and the Pd(0) catalyst is generated from a palladium complex with a water-soluble non-reducing phosphine. In other embodiments, the Pd(0) catalyst is generated in situ from a palladium complex (e.g., a Pd(II) complex) and a water-soluble non-reducing phosphine. In some embodiments, the water-soluble non-reducing phosphine comprises a tri(substituted C1-C6 alkyl)phosphine or an unsubstituted or substituted aromatic phosphine or a combination thereof. In some embodiments, the transition metal catalyst is a Pd(0) catalyst generated in situ from a palladium complex and a water-soluble non-reducing tri(substituted C1-C6 alkyl)phosphine. In other embodiments, the transition metal catalyst is a palladium complex and a water-soluble non-reducing tri(substituted C1-C6 alkyl)phosphine. 10 In some embodiments, the palladium complex comprises [Pd(allyl)Cl]2, Na2PdCl4, K2PdCl4, Li2PdCl4, [Pd(allyl)(THPP)]Cl, [Pd(allyl)(THPP)2]Cl, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2 or Pd(NO3)2 or a combination thereof. In other embodiments, the palladium complex comprises [Pd(allyl)Cl]2 or Na2PdCl4. In some embodiments, the tri(substituted C1-C6 alkyl)phosphine is a tri(carboxyl-substituted C1-C6 alkyl)phosphine, wherein one, two or three C1-C6 alkyl groups may be substituted with carboxyl groups. In one example, the tri(substituted C1-C6 alkyl)phosphine is (TCEP). In some other embodiments, one, two or three C1-C6 alkyl groups of the tri(substituted C1-C6 alkyl)phosphine ligand may be substituted with one or more functional groups that improve the water solubility of the phosphine, such as amino, substituted amino, ammonium, -SO3H or sulfonate (-SO3 - ) or a combination thereof. In some embodiments, the tri(substituted C1-C6 alkyl)phosphine is: (DIPA) or (diBuPpropSO3). In some embodiments, the non-reducing aromatic phosphine comprises or is tri(substituted C6-C 10 In some embodiments, the present invention provides a phosphine having a substituted phenyl group, ...
[0116] In some embodiments of the method, the transition metal catalyst is a Pd(0) catalyst, and the Pd(0) catalyst is generated from a palladium complex having an N,N-bidentate non-phosphine ligand. In other embodiments, the N,N-bidentate ligand is selected from the group consisting of: (GSH),
[0117]
[0118] Their salts; wherein R1 is independently -SO3H, -COOH, -PO3H2 or -NMe3 + ; R2 is -(CH2) 1-3and R3 is -SO3H or -COOH. In some embodiments, the molar ratio of the palladium complex to the N,N-bidentate non-phosphine ligand is about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5, or 1:10.
[0119] In some embodiments of the method, the reducing agent is a boron-containing reducing agent. In some embodiments, the boron-containing reducing agent is NH3BH3 or B2(OH)4. In some embodiments, the boron-containing reducing agent is also a phosphine reducing agent. Non-limiting examples of boron-containing phosphine reducing agents include sodium borohydride, borane tetrahydrofuran, lithium borohydride, sodium triacetoxyborohydride, borane dimethylamine, borane dimethyl sulfide, catechol borane, tetrabutylammonium borohydride, borane-ammonia complex, calcium borohydride, magnesium borohydride, potassium borohydride, dichlorophenyl borane, calcium borohydride bis (tetrahydrofuran), triethyl potassium borohydride, borane diphenylphosphine complex, dicyclohexyl iodide borane, tetraethylammonium borohydride, dichloro (diisopropylamino) borane, bromodimethyl borane, diethylmethoxy borane, dichloromethyl diisopropoxy borane, bromodimethyl borane or monobromoborane methyl sulfide. In some embodiments of the method, the pH of the second aqueous solution is from about 7.0 to about 10 or from about 7.5 to about 9.5. In some embodiments of the method, the 3' blocking group has a structure attached to the 3' oxygen of the nucleotide Where R a , R b , R c , R d and R e Each of is independently H, halogen, unsubstituted or substituted C1-C6 alkyl or C1-C6 haloalkyl. In another embodiment, the 3' blocking group of the nucleotide has a structure connected to the 3' oxygen of the nucleotide. In some embodiments of the method, the first aqueous solution or the third aqueous solution comprises at least one Pd(0) scavenger. In yet other embodiments, the Pd(0) scavenger comprises one or more allyl moieties selected from the group consisting of: -O-allyl, -S-allyl, -NR-allyl, and -N-allyl. + RR'-allyl and combinations thereof, wherein R is H, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C2-C6 alkenyl, unsubstituted or substituted C2-C6 alkynyl, unsubstituted or substituted C6-C 10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C3-C 10carbocyclyl or unsubstituted or substituted 5 to 10 membered heterocyclyl; and R' is H, unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl. In yet another embodiment, the Pd(0) scavenger comprising one or more -O-allyl moieties is (N-BocTyr(allyl)-OH) or (allyl-β-D-pyranoglucoside) or a salt thereof. In yet another embodiment, the compound comprises one or more -NR-allyl or -N + The RR'-allyl moiety of the Pd(0) scavenger is Where Z - It is Cl - or F - . In other embodiments, a Pd(0) scavenger comprising one or more allyl moieties is in the first aqueous solution. In some embodiments of the method, the third aqueous solution further comprises at least one Pd(II) scavenger. In other embodiments, the Pd(II) scavenger comprises L-cysteine or sodium thiosulfate. In some embodiments of the method, when step (e) is performed at room temperature, the 3' blocking group of the incorporated nucleotide is removed in less than 5 minutes. In some embodiments of the method, the 3' blocking group of the incorporated nucleotide is removed in about 1 minute. In some embodiments of the method, the solid support comprises an array of fixed target polynucleotides.
[0120] Non-reducing ligand
[0121] In some embodiments, the ligand included to produce the transition metal catalyst is a non-reducing ligand. In some embodiments, the non-reducing ligand may include a water-soluble non-reducing phosphine. In some other embodiments, the non-reducing ligand may include an N,N-bidentate non-phosphine ligand. The transition metal complex (precatalyst) can be mixed with a non-reducing ligand to produce a coordination complex. Separately, at least one reducing agent is required to reduce the transition metal phosphine ligand coordination complex to an active catalyst form. For example, a Pd(II) precatalyst [Pd(allyl)Cl]2 or Na2PdCl4 can form an intermediate Pd(II) coordination complex with a non-reducing phosphine TCEP. In order to convert the Pd(II) intermediate complex into an active catalytic form, a reducing agent (such as a boron-containing reducing agent described herein) is also introduced to reduce the Pd(II) to an active Pd(0) form. Under certain reaction conditions, TCEP itself may not be able to act as a reducing agent because it does not have the correct potential to reduce the Pd(II) complex. Such a reaction pathway may be desirable because it separates the reduction of the transition metal from the coordination of the transition metal. In contrast, certain phosphine ligands can serve the dual purpose of coordinating with the transition metal and reducing the transition metal to an active catalytic form. For example, when Na2PdCl4 is mixed with tris(hydroxypropyl)phosphine (THPP or THP), THPP also serves as a reducing agent to reduce Pd(II) to Pd(0).
[0122] Non-reducing water-soluble phosphine ligands include, for example, tri(substituted C1-C6 alkyl)phosphine, wherein one, two or one, two or three C1-C6 alkyl groups of the tri(substituted C1-C6 alkyl)phosphine ligand may be substituted with one or more functional groups that improve the water solubility of the phosphine, such as amino, substituted amino, ammonium, -SO3H or sulfonate or a combination thereof; and these functional groups cannot be used as electron donors for transition metals, such as reducing Pd(II) to Pd(0). Such tri(substituted C1-C6 alkyl)phosphine may contain at least one substituted C1-C6 alkyl group, but all three C1-C6 alkyl groups do not have to be substituted. Suitable tri(substituted C1-C6 alkyl)phosphine may include tri(carboxyethyl)phosphine (TCEP), 2-(diisopropylphosphinoyl)ethane-1-amine (DIPA) and 3-(di-tert-butylphosphino)propane-1-sulfonate (diBuPpropSO3). Other suitable non-reducing phosphines may be (substituted C1-C6 alkyl)(dicycloalkyl)phosphines, such as 2-(dicyclohexylphosphino)-N,N,N-trimethylethane-1-ammonium (DCPT). Another suitable non-reducing phosphine may be an aromatic phosphine, such as tri(substituted C6-C 10In some embodiments, the tri(substituted phenyl)phosphine is a tri(sulfonate-substituted phenyl)phosphine. Such sulfonate-substituted triphenylphosphine may be in the form of a salt, such as a sodium salt or a potassium salt. In addition, one, two or three phenyl groups of the tri(sulfonate-substituted phenyl)phosphine may be further substituted by a carboxyl group. Exemplary tri(substituted phenyl)phosphine include, but are not limited to:
[0123]
[0124]
[0125] or a salt thereof, such as a sodium or potassium salt, for example tri(2,4-dimethyl-5-sulfophenyl)phosphine trisodium salt (TXPTS). Another suitable non-reducing phosphine may be a (substituted diphenyl)(substituted C1-C6 alkyl)phosphine, such as Other water-soluble phosphines may be suitable non-reducing agents. For example, 1,2-bis(dimethylphosphino)ethane ((diMeP)2Et) can be a suitable non-reducing ligand. Some non-phosphine molecules can be suitable non-reducing ligands, such as N,N-bidentate ligands. In some embodiments, glutathione (GSH) may be a suitable non-reducing ligand.
[0126] Other suitable N,N-bidentate ligands may include, for example
[0127]
[0128]
[0129]
[0130] Their salts; wherein R1 is independently -SO3H, -COOH, -PO3H2 or -NMe3 + ; R2 is -(CH2) 1-3 COOH; and R3 is -SO3H or -COOH. In some other embodiments, the N,N-bidentate ligands described herein may contain additional water-soluble groups, including but not limited to phosphate; (in Each C1-C6 alkyl in is optionally substituted with one or more selected from phosphate, substituted with a substituent);
[0131]
[0132] reducing agent
[0133] Reducing agent can be used to reduce transition metal from its pre-catalytic form to active form, for 3' decapping reaction and / or the cracking of joint according to the present disclosure.In some embodiments, reducing agent contains boron.For example, reducing agent can be borane, disubstituted boric acid (borinic acid), boric acid, boric ester or borohydride.In some embodiments, reducing agent is borane or boric acid.Suitable borane includes diborane, triborane, tetraborane, pentaborane, hexaborane, heptaborane, octaborane, nonaborane, decaborane, borane tetrahydrofuran, borane dimethyl sulfide, catechol borane, dichlorophenyl borane, borane diphenylphosphine complex, dicyclohexyl iodide borane, bromodimethyl borane, diethyl methoxy borane, dimethyl diisopropoxy borane, bromodimethyl borane and monobromo borane methyl sulfide.Suitable borane includes amino borane. Suitable amine-boranes include pyridine-borane, N-heteroaromatic-borane complexes, ammonia borohydride (NH3BH3), borane-ammonia complexes, borane dimethylamine, borane tert-butylamine, borane trimethylamine, borane isopropylamine, dichloro (diisopropylamino) borane and cycloborazine. Suitable boric acids include boric acid, 4-hydroxyphenylboric acid, boron tetrahydride (B2(OH)4), phenylboric acid, 2-thienylboric acid, methylboric acid, cis-propenylboric acid and trans-propenylboric acid. Suitable boric acid esters include allylboronic acid pinacol ester, phenylboronic acid trimethylene glycol ester and diisopropoxymethylborane. Suitable borohydrides include sodium borohydride (Na2BH4), lithium borohydride, calcium borohydride, calcium borohydride bis(tetrahydrofuran), magnesium borohydride, potassium borohydride, potassium triethylborohydride, sodium triacetoxyborohydride, tetraethylammonium borohydride, and tetrabutylammonium borohydride. In some embodiments, the concentration of the reducing agent (such as a boron-containing reducing agent) in the first aqueous solution (also referred to as the cleavage mixture) is about 0.1mM, 0.2mM, 0.3mM, 0.4mM, 0.5mM, 0.6mM, 0.7mM, 0.8mM, 0.9mM, 1mM, 1.5mM, 2mM, 2.5mM, 3mM, 3.5mM, 4mM, 4.5mM, 5mM, 5.5mM, 6mM In one embodiment, the concentration of the reducing agent in the first aqueous solution is about 20 mM.
[0134] Transition Metal Catalysts
[0135] Transition metal catalysts can be used in the reaction with non-reducing ligands and reducing agents to remove the 3' capping group. Suitable transition metals used as catalysts include palladium (Pd) and nickel (Ni). Similar to palladium, the nickel precatalyst can exist in the form of Ni (II), and the active catalytic form is Ni (0).
[0136] Palladium catalyst
[0137] In some embodiments, the Pd catalyst used to remove or cleave the 3' blocking group described herein is water soluble. In some such embodiments, the Pd catalyst is in the form of an active Pd(0). In some cases, the Pd(0) catalyst can be generated in situ by reduction of a Pd complex or a Pd precatalyst (e.g., a Pd(II) complex) with a reagent such as an olefin, an alcohol, an amine, a phosphine, or a metal hydride. Suitable Pd sources include Pd(CH3CN)2Cl2, [Pd(allyl)Cl]2, [Pd(allyl)(THPP)]Cl, [Pd(allyl)(THPP)2]Cl, Na2PdCl4, K2PdCl4, Li2PdCl4, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2, and Pd(NO3)2. In one such embodiment, the Pd(0) complex is generated in situ from an organic or inorganic salt of palladium(II) salt, such as Na2PdCl4 or K2PdCl4. In another embodiment, the palladium source is allylpalladium(II) chloride dimer [(allyl)PdCl]2 or [PdCl(C3H5)]2. In some embodiments, according to the present disclosure, a Pd(0) catalyst is produced in aqueous solution by mixing a Pd(II) complex with a water-soluble non-reducing ligand and a reducing agent. Suitable non-reducing ligands include tri(substituted C1-C6 alkyl)phosphines, such as tri(carboxyethyl)phosphine. (TCEP), 2-(diisopropylphosphinoyl)ethane-1-amine (DIPA), 3-(di-tert-butylphosphino)propane-1-sulfonate (diBuPpropSO3); tri(substituted phenyl)phosphine, such as tri(2,4-dimethyl-5-sulfophenyl)phosphine trisodium salt (TXPTS); (substituted C1-C6 alkyl)(dicycloalkyl)phosphine, such as 2-(dicyclohexylphosphino)-N,N,N-trimethylethane-1-ammonium (DCPT) or a combination thereof. Other water-soluble phosphines, such as 1,2-bis(dimethylphosphino)ethane ((diMeP)2Et) may also be suitable for use as a non-reducing ligand. According to the present disclosure, a suitable reducing agent may contain borane.
[0138] In some embodiments, the palladium catalyst is prepared by mixing [(allyl)PdCl]2 with TCEP in situ. The molar ratio of [(allyl)PdCl]2 to TCEP can be about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5, or 1:10. In one embodiment, the molar ratio of [(allyl)PdCl]2 to TCEP is 1:5. In some other embodiments, the palladium catalyst is prepared by mixing a water-soluble Pd reagent such as Na2PdCl4 or K2PdCl4 with TCEP in situ. The molar ratio of Na2PdCl4 or K2PdCl4 to TCEP can be about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5, or 1:10. In one embodiment, the molar ratio of Na2PdCl4 or K2PdCl4 to TCEP is about 1:3. In another embodiment, Na2PdCl4 or K2PdCl4 is about 1:3. K2 The molar ratio of PdCl4 to TCEP was about 1:3.5.
[0139] The Pd complex and water-soluble phosphine used in the cleavage step of the method described herein can be in a composition or mixture, also referred to as a cleavage mixture. In some additional embodiments, the cleavage mixture can contain additional buffer reagents, such as primary amines, secondary amines, tertiary amines, natural amino acids, non-natural amino acids, carbonates, phosphates or borates, or combinations thereof. In some additional embodiments, the buffer reagents include ethanolamine (EA), tris(hydroxymethyl)aminomethane (Tris), glycine, sodium carbonate, sodium phosphate, sodium borate, dimethylethanolamine (DMEA), diethylethanolamine (DEEA), N,N,N',N'-tetramethylethylenediamine (TMEDA), N,N,N',N'-tetraethylethylenediamine (TEEDA) or piperidinylethanolamine (PipEA or 1-(2-hydroxyethyl)piperidine, having the structure ) or a combination thereof. In one embodiment, one or more buffer reagents include DEEA. In another embodiment, one or more buffer reagents include PipEA. In another embodiment, one or more buffer reagents contain one or more inorganic salts, such as carbonate, phosphate or borate, or a combination thereof. In one embodiment, the inorganic salt is a sodium salt. In some embodiments, the molar ratio of the Pd catalyst to the reducing agent is about 1:100, 1:50, 1:20, 1:10 or 1:5. In some embodiments, the molar ratio of the Pd catalyst to the Pd scavenger comprising one or more allyl moieties is about 1:100, 1:50, 1:20, 1:10 or 1:5. In some other embodiments, the Pd scavenger comprising one or more allyl moieties is a Pd scavenger of the active form Pd(0) of the Pd catalyst.
[0140] In some embodiments, the cleavage conditions of the 3' blocking group are the same as the conditions for cleaving the cleavable linker of the nucleotide. For example, the nucleotide can include a linker portion that is the same as the 3' blocking group. In other embodiments, the cleavage conditions of the 3' blocking group are different from the conditions for cleaving the cleavable linker of the nucleotide.
[0141] Nickel Catalyst
[0142] In some embodiments, the Ni catalyst for removing or cracking the 3' blocking group described herein is water soluble. In some such embodiments, the Ni complex is a Ni(O) complex. In some cases, the Ni(O) complex can be produced in situ from the reduction of a Ni complex or a Ni precatalyst (e.g., a Ni(II) complex) by reagents such as olefins, alcohols, amines, phosphines, or metal hydrides. In some embodiments, the Ni(II) compound is NiCl2. In some embodiments, according to the present disclosure, by mixing a Ni(II) complex with a water-soluble non-reducing ligand and a reducing agent, a Ni(O) catalyst is produced in an aqueous solution. For example, by mixing NiCl2 with 1 to 10 molar equivalents of a water-soluble non-reducing ligand to prepare a Ni complex. Suitable non-reducing ligands include tri(substituted C1-C6 alkyl) phosphine, such as TCEP, DIPA, diBuPpropSO3, TXPTS, DCPT, or a combination thereof. Other water-soluble phosphines, such as 1,2-bis(dimethylphosphino)ethane ((diMeP)2Et) may also be suitable for use as non-reducing ligands. According to the present disclosure, a suitable reducing agent may contain borane. In some embodiments, according to the present disclosure, a Ni(0) catalyst is produced in aqueous solution by mixing a Ni(II) complex with a water-soluble reducing ligand (e.g., THPP).
[0143] Palladium scavenger
[0144] Certain aspects of the present disclosure relate to employing alternative palladium scavengers in several steps of sequencing by synthesis, wherein at least one palladium scavenger comprises one or more allylic moieties (e.g., -O-allyl, -S-allyl, -NR-allyl, or -N-allyl). + RR'-allyl or a combination thereof), as a competitive substrate (i.e., a Pd(0) scavenger) for consuming any remaining Pd(0) attached to the nucleic acid. These palladium scavengers are described in WO / 2022 / 243480, which is incorporated by reference in its entirety. The sequencing methods described herein substantially improve sequencing metrics (e.g., reducing phasing values and pre-phasing values) and can also reduce sequencing time per cycle by eliminating certain post-cleavage processing steps.
[0145] In some embodiments of any of the methods described herein, a palladium scavenger comprising one or more allyl moieties is in the first aqueous solution. In some cases, the first aqueous solution is also referred to as an incorporation mixture (IMX). In some such embodiments, this palladium scavenger is compatible with other sequencing reagents in the first aqueous solution, and in addition to one or more different types of nucleotides, the first aqueous solution may also include a polymerase (such as a DNA polymerase). In some such embodiments, the polymerase is a DNA polymerase, such as a mutant of a 9°N polymerase (e.g., those disclosed in WO 2005 / 024010, which is incorporated by reference), for example, Pol 812, Pol 1901, Pol 1558, or Pol 963. The amino acid sequences of Pol 812, Pol 1901, Pol 1558, or Pol 963 DNA polymerases are described in, for example, U.S. Patent Publication Nos. 2020 / 0131484A1 and 2020 / 0181587A1, which are incorporated herein by reference. In some embodiments, the first aqueous solution also includes one or more buffers. The buffer may include primary amines, secondary amines, tertiary amines, natural amino acids or non-natural amino acids, or a combination thereof. In other embodiments, the buffer includes ethanolamine or glycine, or a combination thereof. In one embodiment, the buffer includes glycine, or is glycine. In other embodiments, the palladium scavenger comprising one or more allyl moieties does not require a separate washing step before the next incorporation cycle. In other embodiments, the palladium scavenger in the first aqueous solution is a Pd(0) scavenger as described herein. In some embodiments, the Pd(0) scavenger is premixed with one or more of the DNA polymerase and / or four types of nucleotides (e.g., dATP, dCTP, dGTP and dTTP or dUTP). In other embodiments, the Pd(0) scavenger is stored separately from the DNA polymerase and / or one or more of the four types of nucleotides, and is mixed with these components shortly before the sequencing run begins.
[0146] In some embodiments of any of the methods described herein, the concentration of the Pd(0) scavenger comprising one or more allyl moieties in the first aqueous solution is about 0.1 mM to about 100 mM, 0.2 mM to about 75 mM, about 0.5 mM to about 50 mM, about 1 mM to about 20 mM, or about 2 mM to about 10 mM. In other embodiments, the concentration of the palladium scavenger (e.g., Pd(0) scavenger) is about 0.1 mM, 0.2 mM, 0.3 mM, 0.4 mM, 0.5 mM, 0.6 mM, 0.7 mM, 0.8 mM, 0.9 mM, 1 mM, 1.5 mM, 2 mM, 2.5 mM, 3 mM, 3.5 mM, 4 mM, 4.5 mM, 5 mM, 5.5 mM, 6 mM, 6.5 mM, 7 mM, 7.5 mM, 8 mM, 8.5 mM, 9 mM, 9.5 mM, 10 mM, 12.5 mM, 15 mM, 17.5 mM, or 20 mM, or a range defined by any two of the foregoing values. In other embodiments, the concentration of the palladium scavenger is the concentration in the first aqueous solution. In other embodiments, the pH of the first aqueous solution is about 9.
[0147] In some other embodiments of any of the methods described herein, a palladium scavenger comprising one or more allyl moieties is in solution when one or more fluorescence measurements are performed. In such embodiments, such palladium scavengers are compatible with the sequencing reagents of the scanning solution (also referred to as the scanning mixture). In further embodiments, one or more palladium scavengers do not require a separate washing step prior to the next incorporation cycle. In further embodiments, the palladium scavenger in the scanning solution is a Pd(0) scavenger as described herein.
[0148] In other embodiments of the methods described herein, a palladium scavenger comprising one or more allyl moieties is in the post-cleavage wash solution (i.e., the second aqueous solution). In additional embodiments, the palladium scavenger in the post-cleavage wash solution is a Pd(0) scavenger described herein. In some such embodiments, the post-cleavage wash solution does not comprise lipoic acid or 3,3'-dithiodipropionic acid (DDPA).
[0149] In yet other embodiments of the methods described herein, a palladium scavenger comprising one or more allyl moieties can be present in the first aqueous solution (e.g., incorporated into the mixture) and the second aqueous solution (e.g., post-cleavage wash solution), or in the first aqueous solution and the scanning mixture. In some such embodiments, the post-cleavage wash solution does not comprise lipoic acid or DDPA.
[0150] Non-limiting examples of Pd(0) scavengers comprising one or more -O-allyl or allylic moieties include the following:
[0151] (Compound A), (Compound B, N-BocTyr(allyl)-OH), (Compound C, allyl-β-D-glucopyranoside), (Compound D), (Compound E), (Compound F), (Compound G), (Compound H), (Compound I), (Compound J),
[0152] (Compound K), (Compound L), (Compound M) and (Compound N).
[0153] Non-limiting examples of Pd(0) scavengers comprising one or more -S-allyl moieties include the following:
[0154] Contains one or more -NR-allyl or -N + Non-limiting examples of RR'-allyl moieties of Pd(0) scavengers include the following: Where Z - is an anion (e.g., a halide anion such as F - or Cl - In one embodiment, the palladium scavenger is (Compound O, diallyldimethylammonium chloride, also known as DADMAC).
[0155] In some embodiments of the methods described herein, the method may further use additional palladium scavengers, such as Pd (II) scavengers. In some such embodiments, the use of additional Pd scavengers can improve the phasing value of sequencing indicators. For example, additional Pd scavengers may include isocyanoacetic acid (ICNA) salts, ethyl isocyanoacetate, methyl isocyanoacetate, cysteine (e.g., L-cysteine) or its salts (e.g., N-acetyl-L-cysteine), potassium ethyl xanthate, potassium isopropyl xanthate, glutathione, ethylenediaminetetraacetic acid (EDTA), iminodiacetic acid, nitrilodiacetic acid, trithio-S-triazine, dimethyl dithiocarbamate, dithiothreitol, mercaptoethanol, allyl alcohol, propargyl alcohol, thiol, thiosulfate salts (e.g., sodium thiosulfate or potassium thiosulfate), tertiary amines and / or tertiary phosphine or combinations thereof. In one embodiment, the method also includes the use of L-cysteine or its salts. In another embodiment, the method also includes the use of thiosulfate such as sodium thiosulfate (Na2S2O3). In some embodiments, the additional Pd scavenger is a scavenger of Pd (II). In some such embodiments, the Pd (II) scavenger (e.g., L-cysteine or sodium thiosulfate) is in the first aqueous solution. In other embodiments, the Pd (II) scavenger (e.g., L-cysteine or sodium thiosulfate) is in the washing solution (i.e., the second aqueous solution) after cleavage. In other embodiments, the Pd (II) scavenger (e.g., L-cysteine or sodium thiosulfate) may be present in both the first aqueous solution and the second aqueous solution. In other embodiments, the Pd (II) scavenger (e.g., L-cysteine or sodium thiosulfate) may be present in a scanning mixture (i.e., a solution that performs one or more fluorescence measurements of the incorporated nucleotides). In other embodiments, the Pd (II) scavenger may be present in one or more of the incorporation mixture (e.g., the first aqueous solution), the scanning mixture or the washing solution (e.g., the second aqueous solution) after cleavage. In other embodiments, the concentration of the Pd(II) scavenger (such as L-cysteine or sodium thiosulfate) in the first aqueous solution or the second aqueous solution is about 0.1 mM to about 100 mM, 0.2 mM to about 75 mM, about 0.5 mM to about 50 mM, about 1 mM to about 20 mM, or about 2 mM to about 10 mM. In other embodiments, the concentration of the Pd(II) scavenger (such as L-cysteine or sodium thiosulfate) is about 0.1 mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 6.5 mM, 7 mM, 8 mM, 9 mM, 10 mM, 12.5 mM, 15 mM, 17.5 mM, or 20 mM, or a range defined by any two of the foregoing values. In further embodiments, the Pd(II) scavenger is in the second aqueous solution, and the concentration of the Pd(II) scavenger in the second aqueous solution is about 10 mM.
[0156] In some embodiments of the methods described herein, all Pd scavengers are in the first aqueous solution. In some other embodiments of the methods described herein, all Pd scavengers are in the second aqueous solution. In some other embodiments, one or more Pd scavengers (e.g., Pd(0) scavengers) comprising one or more allyl moieties are in the incorporation mixture (i.e., the first aqueous solution), and the Pd(II) scavenger is in the post-cleavage wash solution (i.e., the second aqueous solution). In another embodiment, the post-cleavage wash solution does not contain lipoic acid or DDPA. In other embodiments, the method does not include a post-cleavage wash step.
[0157] In some embodiments of the methods described herein, the target polynucleotide is fixed to the surface of the substrate. In some other embodiments, the surface comprises a variety of fixed target polynucleotides, such as arrays of different fixed target polynucleotides. In some such embodiments, the substrate includes glass, modified or functionalized glass, plastics, polysaccharides, nylon, nitrocellulose, resins, silica, silicon, modified silicon, carbon, metals, inorganic glass or fiber bundles or combinations thereof. In some other embodiments, the substrate is a flow cell, nanoparticles or beads (such as spherical silica beads, inorganic nanoparticles, magnetic nanoparticles, cadmium base points and cadmium-free points, or the U.S. discloses the beads disclosed in No. 2021 / 0187470A1, which are incorporated by reference). In one embodiment, the substrate is a flow cell including a patterned nanopore separated by a gap region, and wherein the fixed target polynucleotide resides in the patterned nanopore.
[0158] In some embodiments of any of the methods described herein, the method is performed on an automatic sequencing instrument, and wherein the automatic sequencing instrument comprises two light sources operating at different wavelengths (e.g., about 450 nm to about 460 nm, and about 520 nm to about 540 nm, in particular about 460 nm and about 532 nm). In other embodiments, the automatic sequencing instrument comprises a single light source operating at one wavelength.
[0159] Nucleotides with 3' blocking groups
[0160] Some embodiments of the present disclosure relate to a 3' hydroxyl-capping group (such as a nucleotide having a structure attached to the 3' oxygen of a nucleotide) comprising a nucleobase, a ribose or deoxyribose moiety and an unsubstituted or substituted allyl moiety. 3'-capping group) nucleotide molecule, wherein R a , R b , R c , R d and R eEach of is independently H, halogen, unsubstituted or substituted C1-C6 alkyl or C1-C6 haloalkyl. In one embodiment, R a , R b , R c , R d and R e Each is H. In some other embodiments, R a and R b Each is H, and R c , R d and R e At least one of is independently halogen (e.g., fluorine, chlorine) or unsubstituted C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, isobutyl or tert-butyl). c is an unsubstituted C1-C6 alkyl group, and R d and R e Each is H. In another example, R c is H, and R d and R e One or both of is halogen or unsubstituted C1-C6 alkyl. Non-limiting embodiments of the 3'-capping group include In one embodiment, the 3' blocking group is It forms with the 3' oxygen ("AOM") group, the AOM group is connected to the 3' carbon atom of the ribose or deoxyribose moiety. Additional embodiments of the 3' blocking group are described in U.S. Publication No. 2020 / 0216891A1, which is incorporated by reference in its entirety. In any embodiment of the nucleotides described herein, the nucleotide may include a 3' blocked 2-deoxyribose moiety. In addition, the nucleotide may be a nucleoside triphosphate. In another embodiment, the 3' blocking group is an allyl ether group (-O-CH2CH=CH2) connected to the 3' carbon atom of the deoxyribose moiety.
[0161] Labeled nucleotides
[0162] In some embodiments, 3' blocked nucleotides also include detectable labels, and this nucleotide is referred to as labeled nucleotides or fully functionalized nucleotides (WN). Labels (e.g., fluorescent dyes) are conjugated via cleavable joints in a variety of ways, and these ways include hydrophobic attraction, ion attraction, and covalent bonding. In some aspects, dyes are conjugated to nucleotides by covalent bonding realized via cleavable joints. One of ordinary skill in the art understands that the label can be covalently bound to a joint by reacting the functional group (e.g., carboxyl) of the label with the functional group (e.g., amino) of a joint. In some such embodiments, a cleavable joint can include the same part as a 3' blocking group. Therefore, a cleavable joint and a 3' blocking group can be cracked or removed under the same reaction conditions. In some such embodiments, a cleavable joint can include an allyl moiety, specifically a part including the following structure:
[0163] Where R 1a , R 1b , R 2a , R 3a and R 3b Each is independently H, halogen, unsubstituted or substituted C1-C6 alkyl or C1-C6 haloalkyl.
[0164] In some embodiments, the dye can be covalently attached to the oligonucleotide or nucleotide via the nucleotide base. For example, the labeled nucleotide or oligonucleotide can have a label attached to the C5 position of a pyrimidine base or the C7 position of a 7-deazapurine base via a cleavable linker moiety.
[0165] Nucleotide can be marked at the site on sugar or nucleobase.As known in the art, "nucleotide" is composed of nitrogenous base, sugar and one or more phosphate groups.In RNA, the sugar is ribose, and in DNA it is deoxyribose, that is, the sugar lacking the hydroxyl group present in ribose.Nitrogenous base is a derivative of purine (e.g., deazapurine, 7-deazapurine) or pyrimidine.Purine is adenine (A) and guanine (G), and pyrimidine is cytosine (C) and thymine (T), or uracil (U) in the case of RNA.The C-1 atom of deoxyribose is bonded to the N-1 of pyrimidine or the N-9 of purine.Nucleotide is also the phosphate ester of nucleoside, wherein esterification occurs on the hydroxyl group of C-3 or C-5 connected to sugar.Nucleotide is usually monophosphate, diphosphate or triphosphate.
[0166] Although bases are commonly referred to as purines or pyrimidines, it will be appreciated by the skilled artisan that derivatives and analogs that do not change the ability of a nucleotide or nucleoside to undergo Watson-Crick base pairing are available. "Derivative" or "analog" means a compound or molecule whose core structure is identical or very similar to that of the parent compound, but which has a chemical or physical modification that allows the derived nucleotide or nucleoside to be connected to another molecule, such as a different or additional side group. For example, the base can be a deazapurine. In a particular embodiment, the derivative should be able to undergo Watson-Crick pairing. "Derivatives" and "analogs" also include, for example, synthetic nucleotides or nucleoside derivatives with modified base moieties and / or modified sugar moieties. Such derivatives and analogs are discussed in, for example, Scheit, Nucleotide analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90: 543-584, 1990. Nucleotide analogs may also include modified phosphodiester bonds, including phosphorothioate bonds, phosphorodithioate bonds, alkylphosphonate bonds, aniline phosphonate bonds, phosphoramidite bonds, and the like.
[0167] In a particular embodiment, the nucleotide of the label can be enzymatically incorporable and enzymatically extendable. Therefore, the linker portion can have enough length to connect the nucleotide to the compound so that the compound does not significantly interfere with the overall binding and recognition of the nucleic acid replicator to the nucleotide. Therefore, the linker can also include a spacer unit. The spacer distance is, for example, the distance of the nucleotide base from the cleavage site or label.
[0168] The present disclosure also encompasses polynucleotides incorporating nucleotides described herein. Such polynucleotides may be DNA or RNA composed of deoxyribonucleotides or ribonucleotides joined with phosphodiester bonds, respectively. Polynucleotides may include naturally occurring nucleotides combined with at least one modified nucleotide (e.g., labeled with a dye compound) as shown herein, non-naturally occurring (or modified) nucleotides other than the labeled nucleotides described herein, or any combination thereof. Polynucleotides according to the present disclosure may also include non-natural backbone bonds and / or non-nucleotide chemical modifications. It is also contemplated that a chimeric structure consisting of a mixture of ribonucleotides and deoxyribonucleotides comprising at least one labeled nucleotide.
[0169] In some embodiments, the labeled nucleotides described herein comprise or have the structure of Formula (I):
[0170]
[0171] Wherein B is a nucleobase;
[0172] R4 is H or OH;
[0173] R 5 is an allyl-containing 3'-capping group, such as described herein Phosphoramidites;
[0174] R 6 is H, a monophosphate, a diphosphate, a triphosphate, a thiophosphate, a phosphate analog, a reactive phosphorus-containing group, or a hydroxyl protecting group;
[0175] L is a linker containing an allyl moiety, such as and
[0176] L 1 and L 2 Each is independently an optionally present linker moiety.
[0177] In some embodiments of the nucleotides described herein, R 1a , R 1b , R 2a , R 3a and R 3b Each is H. In other embodiments, R 1a , R 1b , R 2a ,' 3a and R 3b At least one of is halogen (e.g., fluorine, chlorine) or unsubstituted C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, isobutyl or tert-butyl). In some such cases, R 1a and R 1b Each is H, and R 2a , R 3a and R 3b At least one of them is unsubstituted C1-C6 alkyl or halogen (e.g., R 2a is an unsubstituted C1-C6 alkyl group, and R 3a and R 3b Each is H; or R 2a is H, and R 3a and R 3b One or both of are halogen or unsubstituted C1-C6 alkyl). In one embodiment, the cleavable linker or L comprises (“AOL” connector portion).
[0178] In some embodiments of the nucleotides described herein, the nucleobase ("B" in formula (I)) is a purine (adenine or guanine), a deaza purine, or a pyrimidine (e.g., cytosine, thymine, or uracil). In other embodiments, the deaza purine is a 7-deaza purine (e.g., 7-deaza adenine or 7-deaza guanine). Non-limiting examples of B include Their optionally substituted derivatives and analogs. In some additional embodiments, the labeled nucleobase comprises the structure
[0179] In some other embodiments of the nucleotides described herein, R in formula (I) 5 is a phosphoramidite. In such embodiments, R 6 is an acid-cleavable hydroxyl protecting group that allows subsequent monomer coupling under automated synthesis conditions.
[0180] In some embodiments of the nucleotides described herein, L 1 exists, and L 1 In some further embodiments, L 1 include In other embodiments, the asterisk * indicates L 1 The point of attachment to a nucleobase (eg, C5 for a pyrimidine base, or C7 for a 7-deazapurine base).
[0181] Additional embodiments of nucleosides or nucleotides described herein include those having Formula (Ia), (Ia'), (Ib), (Ic), (Ic'), or (Id):
[0182]
[0183]
[0184] In some additional embodiments of the nucleotides described herein, L 2 exists, and L 2 include wherein n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and the phenyl moiety is optionally substituted. In some such embodiments, n is 5, and L 2 The phenyl moiety of is unsubstituted. In some other embodiments, R 4 is H. In some additional embodiments, -OR 6 It's triphosphate.
[0185] In any of the nucleotide embodiments described herein, the cleavable linker or L 1 / L 2 It may also contain a disulfide moiety or an azide moiety (such as ) or a combination thereof. L 1 or L 2 Additional non-limiting examples of linker moieties in include:
[0186]
[0187] Additional linker moieties are disclosed in WO 2004 / 018493 and U.S. Publication Nos. 2016 / 0040225 and 2021 / 0403500, which are incorporated herein by reference.
[0188] Non-limiting exemplary labeled nucleotides as described herein include:
[0189]
[0190]
[0191] wherein L represents a cleavable linker (optionally including L as described herein 2 ), R represents a ribose or deoxyribose moiety as described above, or a ribose or deoxyribose moiety substituted with one, two or three phosphates at the 5' position.
[0192] In some embodiments, non-limiting exemplary fluorescent dye conjugates are shown below:
[0193]
[0194]
[0195] wherein PG represents a 3' capping group as described herein; n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and m is 0, 1, 2, 3, 4 or 5. In one embodiment, -O-PG is AOM. In one embodiment, n is 5. Refers to the point of attachment of the dye to the cleavable linker as a result of the reaction between the amino group of the linker moiety and the carboxyl group of the dye.
[0196] Various fluorescent dyes can be used as detectable labels in the present disclosure, especially those dyes that can be excited by blue light (for example, about 450nm to about 460nm) or green light (for example, about 520nm to about 540nm). These dyes can also be referred to as "blue dye" and "green dye" respectively. The example of various types of blue dyes, including but not limited to coumarin dyes, color quinoline dyes and containing double boron heterocyclic compounds, is disclosed in U.S. Publication No. 2018 / 0094140, No. 2018 / 0201981, No. 2020 / 0277529, No. 2020 / 0277670, No. 2021 / 0188832, No. 2022 / 0195517, No. 2022 / 0380389 and No. 2023 / 0313292, each of which is incorporated herein by reference in its entirety. Examples of green dyes include cyanine or polymethine dyes disclosed in International Publication Nos. WO2013 / 041117, WO2014 / 135221, WO 2016 / 189287, WO2017 / 051201, and WO2018 / 060482A1, each of which is incorporated by reference in its entirety.
[0197] In any of the embodiments of the nucleotides described herein, the nucleotide comprises a 2' deoxyribose moiety (ie, R 4 In certain other aspects, the 2' deoxyribose contains one, two or three phosphate groups at the 5' position of the sugar ring. In certain other aspects, the nucleotides described herein are nucleotide triphosphates (ie, -OR 6 to form triphosphates of formula (I) and (Ia) to (Id).
[0198] Additional embodiments of the present disclosure relate to oligonucleotides or polynucleotides comprising nucleosides or nucleotides described herein. In some such embodiments, the oligonucleotides or polynucleotides are hybridized with a template or a target polynucleotide. In some such embodiments, the template polynucleotide is fixed on a solid support.
[0199] Additional embodiments of the present disclosure relate to solid supports comprising an array of a plurality of immobilized template or target polynucleotides, and at least a portion of such immobilized template or target polynucleotides are hybridized to an oligonucleotide or polynucleotide comprising nucleosides or nucleotides described herein.
[0200] The present application will also be further described with reference to DNA, however the description will also apply to RNA, PNA and other nucleic acids unless otherwise indicated.
[0201] Cleavage conditions for cleavable linkers
[0202] In any embodiment of nucleotides or nucleosides described herein, the 3' blocking group and the cleavable linker (and the attached label) can be removed under the same or substantially the same chemical reaction conditions, for example, the 3' blocking group and the detectable label can be removed in a single chemical reaction. In other embodiments, the 3' blocking group and the detectable label are removed in two separate steps.
[0203] The cleavable linkers described herein can be removed or cleaved under various chemical conditions. Non-limiting cleavage conditions include palladium catalysts such as Pd(II) complexes (e.g., Pd(OAc)2, allyl chloride Pd(II) dimers [(allyl)PdCl]2 or Na2PdCl4) in the presence of water-soluble phosphine ligands, such as tris(hydroxypropyl)phosphine (THPP or THP), tris(hydroxymethyl)phosphine and / or tris(2-carboxyethyl)phosphine (TCEP), in the presence or absence of a reducing agent. Non-limiting cleavage conditions include nickel catalysts such as Ni(II) compounds (NiCl2) in the presence of phosphine ligands, such as tris(hydroxypropyl)phosphine, tris(hydroxymethyl)phosphine and / or tris(2-carboxyethyl)phosphine. In some embodiments, the 3' capping group can be cleaved under the same or substantially the same cleavage conditions as those used for the cleavable linker.
[0204] Compatible with linearization
[0205] In order to maximize the throughput of nucleic acid sequencing reactions, it is advantageous to be able to sequence multiple template molecules in parallel. Parallel processing of multiple templates can be achieved by using nucleic acid array technology. These arrays are usually composed of a high-density matrix of polynucleotides that are fixed to a solid carrier material.
[0206] WO 98 / 44151 and WO 00 / 18957 have all described nucleic acid amplification methods, and it allows amplification products to be fixed on solid carriers to form arrays, and these arrays are made up of clusters or " colonies ", and wherein clusters or " colonies " are formed by multiple identical immobilized polynucleotide chains and multiple identical immobilized complementary chains. This type of array is referred to as " clustered array " in this article. The nucleic acid molecules present in the DNA colonies on the clustered array prepared according to these methods can provide templates for sequencing reactions, for example as described in WO 98 / 44152. The product of solid phase amplification reaction (such as those described in WO 98 / 44151 and WO 00 / 18957) is a so-called " bridging " structure, and these structures are formed by annealing paired immobilized polynucleotide chains and immobilized complementary chains (both chains are connected to the solid carrier at 5 ' ends). In order to provide a more suitable template for nucleic acid sequencing, it is preferred to remove substantially all or at least a portion of one of the immobilized chains of the " bridging " structure, so as to produce a template that is at least partially single-stranded. Therefore, the single-stranded portion of the template will be available for hybridization with the sequencing primer. The process of removing all or part of an immobilized strand in a "bridging" double-stranded nucleic acid structure is called "linearization". There are many ways of linearization, including but not limited to enzymatic cleavage, photochemical cleavage, or chemical cleavage. Non-limiting examples of linearization methods are disclosed in PCT Publication No. WO 2007 / 010251, U.S. Patent Publication No. 2009 / 0088327, U.S. Patent Publication No. 2009 / 0118128, and U.S. Patent Publication No. 2019 / 0352327, which are incorporated by reference in their entirety.
[0207] In some embodiments, the conditions for removing the 3' blocking group and / or the cleavable linker are also compatible with linearization methods, such as chemical linearization methods involving the use of a Pd complex and a phosphine. In some embodiments, the Pd complex is a Pd(II) complex (e.g., Pd(OAc)2, [(allyl)PdCl]2, K2PdCl4, or Na2PdCl4), which generates Pd(0) in situ in the presence or absence of a reducing agent in the presence of a water-soluble phosphine as described herein.
[0208] Sequencing by Synthesis Implementation and Alternatives
[0209] Alternatively, unlabeled nucleotides and affinity reagents containing fluorescent dyes described herein can also be used to carry out sequencing methods described herein. For example, in the incorporation mixture of step (a), one type, two types, three types or each type of four different types of nucleotides (e.g., dATP, dCTP, dGTP and dTTP or dUTP) can be unlabeled. Each type of four types of nucleotides (e.g., dNTP) has a 3' blocking group to ensure that only a single base can be added to the 3' end of the primer polynucleotide by a polymerase. After incorporating unlabeled nucleotides in step (b), the remaining unincorporated nucleotides are washed off. Affinity reagents are then introduced, which specifically recognize and combine the dNTPs incorporated to provide an extension product containing the labeling of the dNTPs incorporated. The use of unlabeled nucleotides and affinity reagents in synthetic sequencing has been disclosed in WO 2018 / 129214 and WO 2020 / 097607. In addition, post-incorporation labeling sequencing methods have been described in U.S. Publication No. 2023 / 0383342A1 and U.S. Serial No. 63 / 579897, each of which is incorporated herein by reference. The modified sequencing method of the present disclosure using unlabeled nucleotides may include the following steps:
[0210] (a') contacting a solid support with a sequencing primer under hybridization conditions, wherein the solid support comprises a plurality of target polynucleotides immobilized thereon; and the sequencing primer is complementary to at least a portion of the target polynucleotide;
[0211] (b') contacting the solid support with a first aqueous solution comprising a DNA polymerase and one or more of four different types of nucleotides, wherein each of the nucleotides comprises a 3' blocking group comprising an unsubstituted or substituted allyl moiety as described herein, under conditions suitable for DNA polymerase-mediated primer extension;
[0212] (c') contacting the extended copy polynucleotide with a set of affinity reagents under conditions where one of the affinity reagents specifically binds to the incorporated unlabeled nucleotide to provide a labeled extended copy polynucleotide;
[0213] (d') imaging the solid support and performing one or more fluorescence measurements of the extended copy polynucleotide; and
[0214] (e') removing the 3' blocking group of the incorporated nucleotide in a second aqueous solution comprising a transition metal catalyst and one or more reducing agents, wherein the transition metal catalyst is generated by a palladium or nickel complex with a water-soluble non-reducing tri(substituted C1-C6 alkyl)phosphine, and wherein the one or more reducing agents include a boron-containing reducing agent.
[0215] In some embodiments of the modified sequencing method described herein, the method also includes removing affinity reagent from the incorporated nucleotide. In still other embodiments, 3' blocking groups and affinity reagent are removed in the same reaction. In some embodiments, the method also includes step (f') washing the solid support with the third aqueous washing solution. In other embodiments, steps (b') to (f') are repeated at least 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 cycles to determine the target polynucleotide sequence. In some embodiments, the affinity reagent group can include a first affinity reagent that specifically binds to the nucleotide of the first type, a second affinity reagent that specifically binds to the nucleotide of the second type, and a third affinity reagent that specifically binds to the nucleotide of the third type. In some other embodiments, each affinity reagent in the first affinity reagent, the second affinity reagent and the third affinity reagent includes a detectable label that can be distinguished by the spectrum. In some embodiments, affinity reagents may include protein tags, antibodies (including but not limited to binding fragments of antibodies, single-chain antibodies, bispecific antibodies, etc.), aptamers, knottins, affimers, or any other known reagents that bind to incorporated nucleotides with suitable specificity and affinity. In one embodiment, at least one affinity reagent is an antibody or protein tag. In another embodiment, at least one of the first type of affinity reagent, the second type of affinity reagent, and the third type of affinity reagent is an antibody or protein tag comprising one or more detectable labels (e.g., multiple copies of the same detectable label), wherein the detectable label is or includes a diboron dye portion as described herein.
[0216] Some embodiments include pyrosequencing technology. Pyrosequencing detects the release of inorganic pyrophosphate (PPi) when a specific nucleotide is incorporated into a nascent chain (Ronaghi, M., Karamohamed, S., Pettersson, B., Uhlen, M. and Nyren, P. (1996) "Real-time DNA sequencing using detection of pyrophosphate release." Analytical Biochemistry 242 (1), 84-9; Ronaghi, M. (2001) "Pyrosequencing sheds light on DNA sequencing" Genome Res. 11 (1), 3-11; Ronaghi, M., Uhlen, M. and Nyren, P. (1998) "A sequencing method based on real-time pyrophosphate." Science 281 (5375), 363; U.S. Patent Nos. 6,210,891, 6,258,568 and 6,274,320, the disclosures of which are incorporated herein by reference in their entirety). In pyrophosphate sequencing, the released PPi can be detected by immediate conversion to ATP by adenosine triphosphate (ATP) sulfurylase, and the level of ATP generated is detected by photons generated by luciferase. The nucleic acids to be sequenced can be attached to features in an array, and the array can be imaged to capture chemiluminescent signals generated by the incorporation of nucleotides at the features of the array. Images can be obtained after treating the array with a specific nucleotide type (e.g., A, T, C or G). The images obtained after adding each nucleotide type will differ in which features in the array are detected. These differences in the images reflect the different sequence contents of the features on the array. However, the relative position of each feature will remain unchanged in the image. Images can be stored, processed and analyzed using the methods described herein. For example, images obtained after treating the array with each different nucleotide type can be processed in the same manner as exemplified herein for images obtained from different detection channels for a reversible terminator-based sequencing method.
[0217] In another exemplary type of SBS, cycle sequencing is accomplished by stepwise addition of reversible terminator nucleotides comprising, for example, cleavable or photobleachable dye labels, as described, for example, in WO 04 / 018497 and U.S. Pat. No. 7,057,026, the disclosures of which are incorporated herein by reference. This method is commercialized by Solexa (now Illumina, Inc.) and is also described in WO 91 / 06678 and WO 07 / 123,744, each of which is incorporated herein by reference. The availability of fluorescently labeled terminators, in which not only termination can be reversed but also the fluorescent label can be cleaved, facilitates efficient cyclic reversible termination (CRT) sequencing. Polymerases can also be co-engineered to efficiently incorporate and extend from these modified nucleotides.
[0218] Preferably, in the sequencing embodiment based on reversible terminator, the label does not substantially inhibit extension under SBS reaction conditions. However, the detection label can be removable, such as removed by cleavage or degradation. Images can be captured after the label is incorporated into the arrayed nucleic acid feature. In a specific embodiment, each cycle involves four different nucleotide types being delivered to the array simultaneously, and each nucleotide type has a label that is spectrally different. Four images can then be obtained, each image using a detection channel that is selective to one label in the four different labels. Alternatively, different nucleotide types can be added sequentially, and the image of the array can be obtained between each addition step. In such embodiments, each image will show the nucleic acid feature of the nucleotide that has been incorporated with a specific type. Due to the different sequence content of each feature, different feature will be present or not present in different images. However, the relative position of the feature will remain unchanged in the image. The image obtained by such reversible terminator-SBS method can be stored, processed and analyzed as described herein. After the image capture step, the label can be removed, and the reversible terminator part can be removed, so that the subsequent cycle of nucleotide addition and detection can be performed. Removing labels after they have been detected in a particular cycle and before subsequent cycles can provide the advantage of reducing background signal and crosstalk between cycles. Examples of useful labeling and removal methods are set forth below.
[0219] Some embodiments can use less than four different marks to use the detection of four different nucleotides.For example, the method and system described in the material of the combined U.S. Patent No. 2013 / 0079232 can be used to perform SBS.As a first example, a pair of nucleotide types can be detected at the same wavelength, but based on the intensity difference of a member in the pair relative to another member, or based on a member in the pair causing a change (for example, by chemical modification, photochemical modification or physical modification) that a signal that is obvious compared to the signal of another member of the pair detected appears or disappears.As a second example, three of the four different nucleotide types can be detected under specific conditions, and the fourth nucleotide type lacks a mark (for example, a minimum detection caused by background fluorescence, etc.) that can be detected under those conditions or detected minimally under those conditions.The first three nucleotide types can be determined to be incorporated into nucleic acid based on the presence of its corresponding signal, and the fourth nucleotide type can be determined to be incorporated into nucleic acid based on the absence of any signal or the minimum detection of any signal.As a third example, a nucleotide type may include a mark detected in two different channels, and other nucleotide types are detected in no more than one channel. The three exemplary configurations described above are not considered mutually exclusive and can be used in various combinations. An exemplary embodiment combining all three examples is a fluorescence-based SBS method that uses a first nucleotide type detected in a first channel (e.g., dATP with a label detected in the first channel when excited by a first excitation wavelength), a second nucleotide type detected in a second channel (e.g., dCTP with a label detected in the second channel when excited by a second excitation wavelength), a third nucleotide type detected in both the first channel and the second channel (e.g., dTTP with at least one label detected in both channels when excited by the first excitation wavelength and / or the second excitation wavelength), and a fourth nucleotide type that lacks a label detected or minimally detected in either channel (e.g., dGTP without a label).
[0220] In addition, as described in the materials of the incorporated U.S. Publication No. 2013 / 0079232, sequencing data can be obtained using a single channel. In such so-called single dye sequencing methods, a first nucleotide type is labeled, but the label is removed after the first image is generated, and a second nucleotide type is labeled only after the first image is generated. A third nucleotide type retains its label in both the first image and the second image, and a fourth nucleotide type remains unlabeled in both images.
[0221] Some embodiments can utilize sequencing technology while connecting. Such technology utilizes DNA ligase to incorporate oligonucleotides and recognize the incorporation of such oligonucleotides. Oligonucleotides generally have different labels related to the identity of specific nucleotides in the sequence to which the oligonucleotides hybridize. As with other SBS methods, images can be obtained after the array of nucleic acid features is treated with labeled sequencing reagents. Each image will show the nucleic acid features into which a specific type of label has been incorporated. Due to the different sequence content of each feature, different features will be present or absent in different images, but the relative position of the features will remain unchanged in the image. Images obtained by sequencing methods based on connection can be stored, processed and analyzed as described herein. Exemplary SBS systems and methods that can be used with the methods and systems described herein are described in U.S. Patent Nos. 6,969,488, 6,172,218 and 6,306,597, and the disclosures of these patents are incorporated herein by reference in their entirety.
[0222] Some embodiments may utilize nanopore sequencing (Deamer, DW and Akeson, M. "Nanopores and nucleic acids: prospects for ultrarapid sequencing." Trends Biotechnol. 18, 147-151 (2000); Deamer, D. and D. Branton, "Characterization of nucleic acids by nanopore analysis," Acc. Chem. Res. 35: 817-825 (2002); Li, J., M. Gershow, D. Stein, E. Brandin and J. A. Golovchenko, "DNA molecules and configurations in a solid-state nanopore microscope," Nat. Mater. 2: 611-615 (2003), the disclosures of which are incorporated herein by reference in their entirety). In such embodiments, the target nucleic acid passes through a nanopore. The nanopore may be a synthetic pore or a biological membrane protein, such as α-hemolysin. As the target nucleic acid passes through the nanopore, each base pair can be identified by measuring the fluctuations in the conductivity of the pore. (U.S. Pat. No. 7,001,792; Soni, GV and Meller, "A. Progress toward ultrafast DNA sequencing using solid-state nanopores," Clin. Chem. 53, 1996-2001 (2007); Healy, K. "Nanopore-based single-molecule DNA analysis," Nanomed. 2, 459-481 (2007); Cockroft, SL, Chu, J., Amorin, M. and Ghadiri, MR "A single-molecule nanopore device detects DNA polymerase activity with single-nucleotide resolution," J. Am. Chem. Soc. 130, 818-820 (2008), the disclosures of which are incorporated herein by reference in their entirety). The data obtained from nanopore sequencing can be stored, processed and analyzed as described herein. In particular, according to the exemplary processing of optical images and other images described herein, the data can be processed like an image.
[0223] Some other embodiments of the sequencing method relate to the use of 3'-terminated nucleotides described herein in nanoball sequencing technology, such as those described in U.S. Patent No. 9,222,132, the disclosure of which is incorporated herein by reference. A large number of discrete DNA nanoballs can be produced by a rolling circle amplification (RCA) process. The nanoball mixture is then distributed on a patterned glass slide surface containing features that allow a single nanoball to be associated with each position. During the DNA nanoball production process, the DNA is fragmented and then connected to the first of the four adapter sequences. The template is amplified, circularized, and then cleaved with a type II endonuclease. A second set of adapters is added, followed by amplification, circularization, and cleavage. The process is repeated for the remaining two adapters. The final product is a circular template with four adapters, each of which is separated by a template sequence. The library molecules undergo a rolling circle amplification step to produce a large number of concatemers called DNA nanoballs, which are then deposited on a flow cell. Goodwin et al., “Coming of age: ten years of next-generation sequencing technologies,” Nat Rev Genet. 2016;17(6):333-51.
[0224] Some embodiments may utilize methods involving real-time monitoring of DNA polymerase activity. Nucleotide incorporation may be detected by fluorescence resonance energy transfer (FRET) interactions between a polymerase carrying a fluorophore and a γ-phosphate labeled nucleotide (as described, for example, in U.S. Pat. Nos. 7,329,492 and 7,211,414, both of which are incorporated herein by reference), or may be detected with zero-mode waveguides (as described, for example, in U.S. Pat. No. 7,315,019, which is incorporated herein by reference), and may be detected using fluorescent nucleotide analogs and engineered polymerases (as described, for example, in U.S. Pat. No. 7,405,281 and U.S. Publication No. 2008 / 0108082, both of which are incorporated herein by reference). Illumination can be limited to the z-scale volume around the surface-tethered polymerase, so that the incorporation of fluorescently labeled nucleotides can be observed with low background (Levene, MJ et al. "Zero-mode waveguides for single-molecule analysis at high concentrations," Science 299, 682-686 (2003); Lundquist, PM et al. "Parallel confocal detection of singlemolecules in real time," Opt. Lett. 33, 1026-1028 (2008); Korlach, J. et al. "Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nano structures," Proc. Natl. Acad. Sci. USA 105, 1176-1181 (2008), the disclosures of which are incorporated herein by reference in their entirety). Images obtained by such methods can be stored, processed, and analyzed as described herein.
[0225] Some SBS embodiments include detecting the proton released when nucleotides are incorporated into extension products. For example, the sequencing based on the detection of the released proton can use the electric detector and related technology commercially available from Ion Torrent (Guilford, CT, Life Technologies subsidiary), or the sequencing method and system described in No. 2009 / 0026082, No. 2009 / 0127589, No. 2010 / 0137143 and No. 2010 / 0282617 (all of which are disclosed and incorporated herein by reference) in the U.S. The method for amplifying target nucleic acid using kinetic exclusion set forth herein can be easily applied to the substrate for detecting protons. More specifically, the method set forth herein can be used to produce an amplicon clone colony for detecting protons.
[0226] The above-mentioned SBS method can be advantageously carried out in a variety of formats so that a plurality of different target nucleic acids are manipulated simultaneously. In a specific embodiment, different target nucleic acids can be processed in a common reaction vessel or on the surface of a specific substrate. This allows to conveniently deliver sequencing reagents, remove unreacted reagents and detect incorporation events in a variety of ways. In the embodiment using the target nucleic acid of surface binding, the target nucleic acid can be an array format. In the array format, the target nucleic acid can be attached to the surface in a spatially distinguishable manner generally. The target nucleic acid can be attached by direct covalent attachment, attached to beads or other particles or attached to polymerase or other molecules attached to the surface to combine. The array can include a single copy of the target nucleic acid at each site (also referred to as a feature portion), or multiple copies with the same sequence can be present at each site or feature portion. Multiple copies can be produced by an amplification method (such as bridge amplification or emulsion PCR as described in further detail below).
[0227] The methods described herein may use arrays having features at any of a variety of densities, including, for example, at least about 10 features / cm 2 , 100 features / cm 2 , 500 features / cm 2 , 1,000 features / cm 2 , 5,000 features / cm 2 , 10,000 features / cm 2 , 50,000 features / cm 2 , 100,000 features / cm 2 , 1,000,000 features / cm 2 , 5,000,000 features / cm 2 or higher.
[0228] The advantage of the method described herein is that they provide rapid and effective detection of multiple target nucleic acids in parallel. Therefore, the present disclosure provides an integrated system that can use technology known in the art (such as those illustrated above) to prepare and detect nucleic acids. Therefore, the integrated system of the present disclosure may include a fluid component that can deliver amplification reagents and / or sequencing reagents to one or more fixed DNA fragments, and the system includes components such as pumps, valves, reservoirs, fluid pipelines, etc. The circulation cell can be configured for and / or for detecting target nucleic acids in the integrated system. Exemplary circulation cells are described in, for example, the United States Publication No. 2010 / 0111768 and U.S. Patent Application No. 13 / 273,666, each of which is incorporated herein by reference. As illustrated for the circulation cell, one or more fluid components of the integrated system can be used for amplification method and detection method. Taking nucleic acid sequencing embodiment as an example, one or more fluid components of the integrated system can be used for the amplification method described herein and for delivering sequencing reagents in sequencing methods (such as those illustrated above). Alternatively, the integrated system may include a separate fluid system to perform amplification method and perform detection method. Examples of integrated sequencing systems that can generate amplified nucleic acids and also determine nucleic acid sequences include, but are not limited to, MiSeq TM The ELISA platform (Illumina, Inc., San Diego, CA), and the apparatus described in U.S. Patent Application No. 13 / 273,666, which is incorporated herein by reference.
[0229] The array that wherein polynucleotide has been directly connected to the carrier based on silicon dioxide is for example disclosed in WO 00 / 06770 (incorporated herein by reference), wherein polynucleotide is fixed on the glass carrier by the reaction between the epoxy side group on the glass and the internal amino group on the polynucleotide.In addition, polynucleotide can be connected to the solid carrier by the reaction of sulfenyl nucleophilic substance and solid carrier, for example, as described in WO 2005 / 047301 (incorporated herein by reference).Another example of the template polynucleotide of solid support is, wherein template polynucleotide is connected to the hydrogel that is carried on the solid support based on silicon dioxide or other solid supports, for example, as described in WO 00 / 31148, WO 01 / 01143, WO02 / 12566, WO 03 / 014392, U.S. Patent No. 6,465,178 and No. WO 00 / 53812, these patents are separately incorporated herein by reference.
[0230] The specific surface on which the template polynucleotide can be fixed is a polyacrylamide hydrogel. Polyacrylamide hydrogels are described in the references cited above and WO 2005 / 065814, which is incorporated herein by reference. Specific hydrogels that can be used include those described in WO 2005 / 065814 and U.S. Publication No. 2014 / 0079923. In one embodiment, the hydrogel is PAZAM (poly (N- (5-azidoacetamidopentyl) acrylamide-co-acrylamide)).
[0231] The DNA template molecule can be attached to a bead or microparticle, for example, as described in U.S. Pat. No. 6,172,218 (incorporated herein by reference). The attachment to a bead or microparticle can be used for sequencing applications. A bead library can be prepared, wherein each bead contains a different DNA sequence. Exemplary libraries and methods for their generation are described in the following documents: Nature, 437, 376-380 (2005); Science, 309, 5741, 1728-1732 (2005), each of which is incorporated herein by reference. It is within the scope of the present disclosure to sequence an array of such beads using the nucleotides shown herein.
[0232] The template to be sequenced can form part of an "array" on a solid support, in which case the array can take any convenient form. Therefore, the method of the present disclosure is applicable to all types of high-density arrays, including single-molecule arrays, clustered arrays, and bead arrays. The labeled nucleotides disclosed herein can be used to sequence templates on substantially any type of array (including but not limited to those formed by fixing nucleic acid molecules on a solid support).
[0233] However, the labeled nucleotides of the present disclosure are particularly advantageous in the context of sequencing clustered arrays. In clustered arrays, different regions (commonly referred to as sites or features) on the array include multiple polynucleotide template molecules. Generally speaking, the multiple polynucleotide molecules cannot be individually resolved by optical means, but are detected as a whole. Depending on the formation mode of the array, each site on the array can include multiple copies of a single polynucleotide molecule (for example, the site is homogeneous for a specific single-stranded nucleic acid species or double-stranded nucleic acid species) or even multiple copies of a small amount of different polynucleotide molecules (for example, multiple copies of two different nucleic acid species). Clustered arrays of nucleic acid molecules can be produced using techniques known in the art. By way of example, WO 98 / 44151 and WO 00 / 18957 (each of which is incorporated herein) describe a method for amplifying nucleic acids, wherein templates and amplification products are both kept fixed on a solid support, so as to form an array composed of clusters or "colonies" of fixed nucleic acid molecules. The nucleic acid molecules present on the clustered arrays prepared according to these methods are suitable templates for sequencing using nucleotides labeled with dye compounds of the present disclosure.
[0234] The labeled nucleotides disclosed herein can also be used to sequence the templates on the single molecule array. The term "single molecule array" ("SMA") as used herein refers to a group of polynucleotide molecules distributed (or arranged) on a solid support, wherein the spacing between any individual polynucleotide and all other polynucleotide molecules of the group makes it possible to distinguish individual polynucleotide molecules individually. Therefore, in some embodiments, the target nucleic acid molecules fixed to the surface of the solid support can be distinguished by optical means. This means that one or more different signals (each signal represents a polynucleotide) will appear in the distinguishable region of the specific imaging device used.
[0235] Single molecule detection can be achieved, wherein the spacing between adjacent polynucleotide molecules on the array is at least 100 nm, more specifically at least 250 nm, more specifically at least 300 nm, and even more specifically at least 350 nm. Therefore, each molecule can be individually resolved and detected as a single molecule fluorescent spot, and the fluorescence from the single molecule fluorescent spot also exhibits single-step photobleaching.
[0236] The terms "individually resolved" and "individually resolved" are used herein to specify that, when visualized, it is possible to distinguish a molecule on an array from its adjacent molecules. The spacing between the individual molecules on the array will be determined in part by the specific techniques used to resolve the individual molecules. The general characteristics of single molecule arrays will be understood by reference to published applications WO 00 / 06770 and WO 01 / 57248, each of which is incorporated herein by reference. Although one use of the nucleotides of the present disclosure is for sequencing reactions while synthesizing, the effectiveness of these nucleotides is not limited to such methods. In fact, these nucleotides can be advantageously used in any sequencing method that requires detection of fluorescent labels attached to nucleotides incorporated into the polynucleotides.
[0237] In particular, the labeled nucleotides disclosed herein can be used in automated fluorescent sequencing protocols, especially fluorescent dye-terminator cycle sequencing based on the chain termination sequencing method of Sanger and colleagues. Such methods typically use enzymes and cycle sequencing to incorporate fluorescently labeled dideoxynucleotides into primer extension sequencing reactions. The so-called Sanger sequencing method and related protocols (Sanger-type) utilize randomized chain termination of labeled dideoxynucleotides.
[0238] Thus, the present disclosure also encompasses labeled nucleotides that are dideoxynucleotides lacking hydroxyl groups at both the 3' and 2' positions, such dideoxynucleotides being suitable for use in Sanger-type sequencing methods and the like.
[0239] It will be appreciated that the labeled nucleotides of the present disclosure incorporating a 3' blocking group may also be used in Sanger methods and related protocols, since the same effect as that achieved by using dideoxy nucleotides may be achieved by using nucleotides having a 3'-OH blocking group: both prevent incorporation of subsequent nucleotides. In cases where nucleotides according to the present disclosure and having a 3' blocking group are to be used in Sanger-type sequencing methods, it will be appreciated that the dye compound or detectable label attached to the nucleotide need not be attached via a cleavable linker, since in each case where a labeled nucleotide of the present disclosure is incorporated; no subsequent incorporation of a nucleotide is required, and therefore no removal of the label from the nucleotide is required.
[0240] Reagent test kit
[0241] The present disclosure also provides a kit for use with a sequencing device, the kit comprising: an aqueous lysis mixture, the aqueous lysis mixture comprising a transition metal catalyst and one or more reducing agents, wherein the transition metal catalyst is produced by a palladium or nickel complex having a water-soluble non-reducing phosphine or an N,N-bidentate non-phosphine ligand. In some embodiments, the one or more reducing agents include a boron-containing reducing agent as described herein. In some embodiments, the transition metal catalyst can be a Pd(0) catalyst, and the Pd(0) catalyst is produced by a palladium complex having a water-soluble non-reducing phosphine. In another embodiment, the Pd(0) catalyst can be produced in situ by a palladium complex and a water-soluble non-reducing tri(substituted C1-C6 alkyl) phosphine as described herein in conjunction with the sequencing method. In yet other embodiments, the palladium complex may include [Pd(allyl)Cl]2, Na2PdCl4, K2PdCl4, Li2PdCl4, [Pd(allyl)(THPP)]Cl, [Pd(allyl)(THPP)2]Cl, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2, or Pd(NO3)2, or a combination thereof. In yet other embodiments, the palladium complex may include [Pd(Allyl)Cl]2 or Na2PdCl4. In some embodiments, the water-soluble non-reducing phosphine includes or is a tri(substituted C1-C6 alkyl)phosphine or a tri(substituted C6-C6 alkyl)phosphine. 10In some embodiments, the tri(substituted C1-C6 alkyl)phosphine is a tri(carboxyl-substituted C1-C6 alkyl)phosphine. In other embodiments, the tri(substituted C1-C6 alkyl)phosphine is TCEP. In some other embodiments, the tri(substituted C1-C6 alkyl)phosphine is DIPA or diBuPpropSO3. In some embodiments, the molar ratio of the palladium complex to the water-soluble non-reducing phosphine is about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5 or 1:10. In some other embodiments, the transition metal catalyst is a Pd(0) catalyst, and the Pd(0) catalyst is produced by a palladium complex having an N,N-bidentate non-phosphine ligand. In some embodiments, the molar ratio of the palladium complex to the N,N-bidentate non-phosphine ligand is about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5 or 1:10. In some embodiments, the boron-containing reducing agent is NH3BH3 or B2(OH)4. In some embodiments, the pH of the aqueous lysis mixture is about 7.0 to about 10 or about 7.5 to about 9.5. Other suitable non-reducing water-soluble phosphines and reducing agents, such as those described above for sequencing methods, can also be used.
[0242] Some embodiments also include a doping mixture, wherein the doping mixture comprises one or more of four different types of nucleotides (e.g., four different types of nucleotides from A, T, C, and G or U; dATP, dTTP, dCTP, and dGTP or dUTP), wherein each of these nucleotides has a 3' blocking group as described herein. In further embodiments, the doping mixture may comprise at least one Pd(0) scavenger as described herein. In further embodiments, the 3' blocking group of the nucleotide has a structure attached to the 3' oxygen of the nucleotide. Where R a , R b , R c , R d and R e Each of is independently H, halogen, unsubstituted or substituted C1-C6 alkyl or C1-C6 haloalkyl. In yet another embodiment, the 3' blocking group of the nucleotide has a structure connected to the 3' oxygen of the nucleotide In some additional embodiments, the Pd(0) scavenger comprises one or more allyl moieties selected from the group consisting of: -O-allyl, -S-allyl, -NR-allyl, and -N-allyl. + RR'-allyl and combinations thereof, wherein R is H, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C2-C6 alkenyl, unsubstituted or substituted C2-C6 alkynyl, unsubstituted or substituted C6-C 10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C3-C 10 carbocyclyl or unsubstituted or substituted 5 to 10 membered heterocyclyl; and R' is H, unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl. In another embodiment, the Pd(0) scavenger comprising one or more -O-allyl moieties is In other embodiments, the alkylene group comprises one or more -NR-allyl or -N + The RR'-allyl moiety of the Pd(0) scavenger is Where Z - It is Cl - or F - In additional embodiments, the incorporation mixture is in lyophilized form.
[0243] Some embodiments of the kit further comprise an aqueous wash solution or a composition capable of being reconstituted into an aqueous wash solution. In some embodiments, the aqueous wash solution comprises at least one Pd(II) scavenger as described herein.
[0244] The present disclosure also provides a box for use with a sequencing device, the box comprising a plurality of chambers, wherein one or more of the plurality of chambers are used with a kit comprising an aqueous lysis mixture as described herein. For example, the box may include two or more separate chambers, one chamber containing an aqueous lysis mixture as described herein, and another chamber containing an incorporation mixture as described herein.
[0245] Example
[0246] Additional embodiments are disclosed in more detail in the following examples, which are not intended to limit the scope of the claims in any way.
[0247] Example 1. Efficiency of Removing 3'-Terminated TCEP with Reducing Agents
[0248] In a solution assay, the efficiency of TCEP as a non-reducing ligand to THPP was tested in the presence and absence of the reducing agent NH3BH3. The substrate used for cleavage was a fully functionalized A nucleotide with a 3'AOM capping group, and the pH of the cleavage mixture was approximately 9.5 under all conditions. The Pd(0) catalyst was generated from the Pd(II) complex Na2PdCl4.
[0249] like Figure 1 As shown, the cleavage mixture with TCEP and NH3BH3 exhibited a higher cleavage rate than THPP, reaching nearly 100% cleavage rate at 1 minute. The cleavage rate of TCEP without a reducing agent was approximately 0, confirming that TCEP itself cannot convert Pd(II) into the active Pd(0) form.
[0250] Example 2. Efficiency of Pd cleavage mixture at neutral pH
[0251] In a solution assay, the efficiency of a cleavage mixture containing TCEP and NH3BH3 at a pH of about 7 was tested relative to a standard Pd cleavage mixture (UCM) containing THPP at two different pHs: about 7 and about 9.5. The UCM is a Pd cleavage mixture used in several Illumina SBS platforms and typically has a pH of 9.5. The substrate used for cleavage is a fully functionalized A nucleotide with a 3' AOM capping group. The Pd(0) catalyst was generated from Na2PdCl4.
[0252] like Figure 2 As shown, UCM at pH 9.5 achieved about 100% cleavage in 5 minutes. TCEP at pH 7 was able to achieve about 90% cleavage at 10 minutes, and about 100% cleavage at 30 minutes. UCM at pH 7 was not as fast, achieving only about 75% cleavage at 50 minutes. The results indicate that TCEP may be suitable for inclusion in reagents where a neutral pH is desired.
[0253] Example 3. Efficiency of TCEP with 50% Pd concentration
[0254] The efficiency of TCEP in the presence of the reducing agent B2(OH)4 in a cleavage mixture with a Pd concentration of 50% was tested for UCM in the presence of the reducing agent B2(OH)4 compared to standard UCM in a solution assay with 50% and 100% Pd. UCM is typically used with 100% Pd. The substrate used for cleavage is a fully functionalized A nucleotide with a 3'AOM capping group, and the pH for all conditions is approximately 9.5.
[0255] like Figure 3As shown, TCEP with 50% Pd achieved greater than 90% cleavage at 5 minutes and nearly 100% cleavage at 10 minutes. UCM with 100% Pd was able to achieve about 100% cleavage at 5 minutes. UCM with 50% Pd reached about 60% cleavage at 10 minutes and about 90% cleavage after 60 minutes. The results indicate that TCEP may be suitable for inclusion in reagents where it is desirable to minimize Pd.
[0256] Example 4. Evaluation of Pd / TCEP / NH3BH3 in sequencing by synthesis
[0257] In the presence of the boron-containing reducing agent NH3BH3 in the Pd cleavage mixture, the Illumina iSeq TM The efficiency of TCEP was tested against a standard UCM (without a reducing agent) containing Pd / THPP. The substrate used for cleavage was a fully functionalized A nucleotide with a 3' AOM blocking group, and the pH for all conditions was approximately 9.5. Figure 4 As shown, the % phasing and % prephasing of sequencing runs performed with the Pd / TCEP / NH3BH3 cleavage mixture are comparable to those of the standard Pd cleavage mixture.
[0258] Example 5. Efficiency of bidentate N,N non-phosphine ligands
[0259] In this example, the test has the structure The N,N-bidentate non-phosphine ligands were used to evaluate their ability to form Pd(0) from the Pd precatalyst Na2PdCl4 (ligand to Pd ratio of 1:2) and their ability to cleave the AOM substrate in the presence of the external reductant NH3BH3. Figure 5A As shown, the N,N-bidentate ligand is able to form Pd(0). The standard UCM (without reducing agent) containing Pd / THPP was used as a control and produced 80,551 RFU, while the Pd(0) active catalyst generated by the N,N-bidentate non-phosphine ligand produced 42,059 RFU.
[0260] Additionally, the cleavage efficiency of Pd catalysts generated from N,N-bidentate non-phosphine ligands was tested.The substrate used for cleavage was a fully functionalized A nucleotide with a 3' AOM capping group. Figure 5BThe percentage cleavage of 3'AOM-terminated substrates after exposure to UCM or a cleavage mixture containing an N,N-bidentate non-phosphine ligand at 1 minute and 60 minutes, respectively, is shown. As shown, the N,N-bidentate non-phosphine ligand cleaved about 14% of the AOM substrate after 1 minute and about 33% of the AOM substrate at 60 minutes, while UCM cleaved about 49.3% of the AOM substrate at 1 minute and about 98.2% of the AOM substrate at 60 minutes. This experiment demonstrates the availability of N,N-bidentate non-phosphine ligands to form active Pd(0) catalysts in chemical cleavage reactions.
Claims
1. A method for determining the sequence of a plurality of target polynucleotides, the method comprising: (a) contacting a solid support with a sequencing primer under hybridization conditions, wherein the solid support comprises a plurality of target polynucleotides immobilized thereon; and the sequencing primer is complementary to at least a portion of the target polynucleotide; (b) contacting the solid support with a first aqueous solution under conditions suitable for DNA polymerase-mediated primer extension, the first aqueous solution comprising a DNA polymerase and one or more types of nucleotides among four different types of nucleotides, wherein each of the nucleotides comprises a 3' blocking group comprising an unsubstituted or substituted allyl group; (c) incorporating one type of nucleotide into the sequencing primer to produce an extended copy polynucleotide; (d) performing one or more fluorescence measurements on the extended copy polynucleotide; (e) removing the 3' blocking group of the incorporated nucleotide in a second aqueous solution comprising a transition metal catalyst and one or more reducing agents, the transition metal catalyst being generated by a palladium or nickel complex having a water-soluble non-reducing phosphine or an N,N-bidentate non-phosphine ligand, and wherein the one or more reducing agents comprise a boron-containing reducing agent; and (f) washing the solid support with a third aqueous solution after removing the 3' blocking group of the incorporated nucleotide.
2. The method of claim 1, further comprising repeating steps (b) to (f) until the sequence of at least a portion of the target polynucleotide is determined.
3. The method of claim 2, wherein steps (b) to (f) are repeated at least 50 times, at least 100 times, at least 150 times, at least 200 times, at least 250 times, or at least 300 times.
4. The method according to any one of claims 1 to 3, wherein the transition metal catalyst is a Pd(0) catalyst, and the Pd(0) catalyst is generated from the palladium complex with the water-soluble non-reducing phosphine.
5. The method according to any one of claims 1 to 4, wherein the water-soluble non-reducing phosphine comprises tri(substituted C1-C6 alkyl)phosphine or tri(substituted C6-C 10 aryl)phosphine or a combination thereof.
6. The method according to claim 5, wherein the transition metal catalyst is a Pd(0) catalyst generated in situ from the palladium complex and the water-soluble non-reducing tri(substituted C1-C6 alkyl)phosphine.
7. The method according to claim 6, wherein the palladium complex comprises [Pd(allyl)Cl]2, Na2PdCl4, K2PdCl4, Li2PdCl4, [Pd(allyl)(THPP)]Cl, [Pd(allyl)(THPP)2]Cl, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2 or Pd(NO3)2 or a combination thereof.
8. The method of claim 7, wherein the palladium complex comprises [Pd(allyl)Cl]2 or Na2PdCl4.
9. The method according to any one of claims 5 to 8, wherein the tri(substituted C1-C6 alkyl)phosphine is a tri(carboxy-substituted C1-C6 alkyl)phosphine.
10. The method of claim 9, wherein the tri(substituted C1-C6 alkyl)phosphine is 11. The method according to any one of claims 5 to 8, wherein the tri(substituted C1-C6 alkyl)phosphine is:
12. The method of any one of claims 1 to 11, wherein the molar ratio of the palladium complex to the water-soluble non-reducing phosphine is about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5 or 1:
10.
13. The method according to any one of claims 1 to 3, wherein the transition metal catalyst is a Pd(0) catalyst, and the Pd(0) catalyst is generated from the palladium complex having the N,N-bidentate non-phosphine ligand.
14. The method of claim 13, wherein the N,N-bidentate ligand is selected from the group consisting of: and their salts; wherein R1 is independently -SO3H, -COOH, -PO3H2 or -NMe3 + ; R2 is -(CH2) 1-3 COOH; and R3 is -SO3H or -COOH.
15. The method according to any one of claims 1 to 14, wherein the boron-containing reducing agent is NH3BH3 or B2(OH)4.
16. The method of any one of claims 1 to 15, wherein the pH of the second aqueous solution is from about 7.0 to about 10 or from about 7.5 to about 9.
5.
17. The method according to any one of claims 1 to 16, wherein the 3' blocking group has a structure connected to the 3' oxygen of the nucleotide Where R a , R b , R c , R d and R e Each of is independently H, halogen, unsubstituted or substituted C1-C6 alkyl or C1-C6 haloalkyl.
18. The method of claim 17, wherein the 3' blocking group of the nucleotide has a structure connected to the 3' oxygen of the nucleotide 19. The method according to any one of claims 1 to 18, wherein the first aqueous solution or the third aqueous solution comprises at least one Pd(0) scavenger.
20. The method of claim 19, wherein the Pd(0) scavenger comprises one or more allyl moieties selected from the group consisting of: -O-allyl, -S-allyl, -NR-allyl, and -N-allyl. + RR'-allyl and combinations thereof, wherein R is H, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C2-C6 alkenyl, unsubstituted or substituted C2-C6 alkynyl, unsubstituted or substituted C6-C 10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C3-C 10 carbocyclyl or unsubstituted or substituted 5- to 10-membered heterocyclyl; and R' is H, unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl.
21. The method of claim 20, wherein the Pd(0) scavenger comprising one or more -O-allyl moieties is (N-BocTyr(allyl)-OH) or (allyl-β-D-glucopyranoside) or a salt thereof.
22. The method of claim 20, wherein the compound comprises one or more -NR-allyl or -N + The Pd(0) scavenger of the RR'-allyl moiety is Z - , where Z - It is Cl - or F - .
23. The method of any one of claims 19 to 22, wherein the Pd(0) scavenger comprising one or more allyl moieties is in the first aqueous solution.
24. The method of any one of claims 1 to 23, wherein the third aqueous solution further comprises at least one Pd(II) scavenger.
25. The method of claim 24, wherein the Pd(II) scavenger comprises L-cysteine or sodium thiosulfate.
26. The method of any one of claims 1 to 25, wherein when step (e) is performed at room temperature, the 3' blocking group of the incorporated nucleotide is removed in less than 5 minutes.
27. The method of claim 26, wherein the 3' blocking group of the incorporated nucleotide is removed within about 1 minute.
28. The method of any one of claims 1 to 27, wherein the solid support comprises an array of immobilized target polynucleotides.
29. A kit for use with a sequencing device, the kit comprising: An aqueous cleavage mixture comprising a transition metal catalyst and one or more reducing agents, wherein the transition metal catalyst is generated from a palladium or nickel complex with a water-soluble non-reducing phosphine or an N,N-bidentate non-phosphine ligand, and wherein the one or more reducing agents include a boron-containing reducing agent.
30. The kit according to claim 29, wherein the transition metal catalyst is a Pd(0) catalyst, and the Pd(0) catalyst is generated from the palladium complex with the water-soluble non-reducing phosphine.
31. The kit according to claim 29 or 30, wherein the water-soluble non-reducing phosphine comprises tri(substituted C1-C6 alkyl)phosphine or tri(substituted C6-C 10 aryl)phosphine or a combination thereof.
32. The kit of claim 31, wherein the transition metal catalyst is a Pd(0) catalyst generated in situ from the palladium complex and the water-soluble non-reducing tri(substituted C1-C6 alkyl)phosphine.
33. The kit of claim 32, wherein the palladium complex comprises [Pd(allyl)Cl]2, Na2PdCl4, K2PdCl4, Li2PdCl4, [Pd(allyl)(THPP)]Cl, [Pd(allyl)(THPP)2]Cl, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2 or Pd(NO3)2 or a combination thereof.
34. The kit of claim 33, wherein the palladium complex comprises [Pd(allyl)Cl]2 or Na2PdCl4.
35. The kit according to any one of claims 31 to 34, wherein the tri(substituted C1-C6 alkyl)phosphine is a tri(carboxy-substituted C1-C6 alkyl)phosphine.
36. The kit of claim 35, wherein the tri(substituted C1-C6 alkyl)phosphine is 37. A kit according to any one of claims 31 to 34, wherein the tri(substituted C1-C6 alkyl)phosphine is:
38. The kit according to any one of claims 29 to 37, wherein the molar ratio of the palladium complex to the water-soluble non-reducing phosphine is about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5、1:4、1:4.5、1:5、1:5.5、1:6、1:6.5、1:7、1:7.5、1:8、1:8.5、 1:9, 1:9.5 or 1:
10.
39. The kit according to claim 29, wherein the transition metal catalyst is a Pd(0) catalyst, and the Pd(0) catalyst is generated from the palladium complex having the N,N-bidentate non-phosphine ligand.
40. The kit according to any one of claims 29 to 39, wherein the boron-containing reducing agent is NH3BH3 or B2(OH)4.
41. The kit of any one of claims 29 to 40, wherein the pH of the aqueous lysis mixture is from about 7.0 to about 10 or from about 7.5 to about 9.
5.
42. The kit of any one of claims 29 to 41, further comprising a spike-in mixture, wherein the spike-in mixture comprises: one or more types of nucleotides among four different types of nucleotides, wherein each of the nucleotides has a 3' capping group comprising an unsubstituted or substituted allyl group; and at least one Pd(0) scavenger.
43. The kit of claim 42, wherein the 3' blocking group of the nucleotide has a structure linked to the 3' oxygen of the nucleotide Where R a , R b , R c , R d and R e Each of is independently H, halogen, unsubstituted or substituted C1-C6 alkyl or C1-C6 haloalkyl.
44. The kit of claim 43, wherein the 3' blocking group of the nucleotide has a structure linked to the 3' oxygen of the nucleotide 45. The kit according to any one of claims 42 to 44, wherein the Pd(0) scavenger comprises one or more allyl moieties selected from the group consisting of: -O-allyl, -S-allyl, -NR-allyl and -N+RR'-allyl and combinations thereof, wherein R is H, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C2-C6 alkenyl, unsubstituted or substituted C2-C6 alkynyl, unsubstituted or substituted C6-C 10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C3-C 10 carbocyclyl or unsubstituted or substituted 5- to 10-membered heterocyclyl; and R' is H, unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl.
46. The kit of claim 45, wherein the Pd(0) scavenger comprising one or more -O-allyl moieties is or their salts.
47. The kit of claim 45, comprising one or more -NR-allyl or -N + The Pd(0) scavenger of the RR'-allyl moiety is - Z, where Z - It is Cl - or F - .
48. The kit of any one of claims 42 to 47, wherein the incorporation mixture is in lyophilized form.
49. A kit according to any one of claims 29 to 48, further comprising an aqueous washing solution or a composition capable of being reconstituted into an aqueous washing solution.
50. The kit of claim 49, wherein the aqueous wash solution comprises at least one Pd(II) scavenger.
51. A box for use with a sequencing device, the box comprising a plurality of chambers, wherein one chamber of the plurality of chambers is used with the kit comprising the aqueous lysis mixture according to any one of claims 29 to 41.
